Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 4.6    
    

PLEDGE AND SECURITY AGREEMENT

dated as of June 30, 2004  

between

EACH OF THE GRANTORS PARTY HERETO  

and 

CREDIT SUISSE FIRST BOSTON,

acting through its Cayman Islands Branch,
  as Collateral Agent 

  

 
 

TABLE OF CONTENTS    
    

	 
	 	Page

	SECTION 1. DEFINITIONS; GRANT OF SECURITY	 	1
	 	1.1    General Definitions	 	1
	 	1.2    Definitions; Interpretation	 	6
	

SECTION 2. GRANT OF SECURITY	
 	

7
	 	2.1    Grant of Security	 	7
	 	2.2    Certain Limited Exclusions	 	7
	

SECTION 3. SECURITY FOR OBLIGATIONS; GRANTORS REMAIN LIABLE	
 	

7
	 	3.1    Security for Obligations	 	7
	 	3.2    Continuing Liability Under Collateral	 	8
	

SECTION 4. REPRESENTATIONS AND WARRANTIES AND COVENANTS	
 	

8
	 	4.1    Generally	 	8
	 	4.2    Equipment and Inventory	 	10
	 	4.3    Receivables	 	11
	 	4.4    Investment Related Property	 	13
	 	4.5    Letter of Credit Rights	 	17
	 	4.6    Intellectual Property	 	18
	 	4.7    Commercial Tort Claims	 	20
	

SECTION 5. ACCESS; RIGHT OF INSPECTION AND FURTHER ASSURANCES; ADDITIONAL GRANTORS	
 	

20
	 	5.1    Further Assurances	 	20
	 	5.2    Additional Grantors	 	21
	

SECTION 6. COLLATERAL AGENT APPOINTED ATTORNEY-IN-FACT	
 	

21
	 	6.1    Power of Attorney	 	21
	 	6.2    No Duty on the Part of Collateral Agent or Secured Parties	 	22
	

SECTION 7. REMEDIES	
 	

23
	 	7.1    Generally	 	23
	 	7.2    Application of Proceeds	 	24
	 	7.3    Sales on Credit	 	24
	 	7.4    Deposit Accounts	 	24
	 	7.5    Investment Related Property	 	24
	 	7.6    Intellectual Property	 	25
	 	7.7    Cash Proceeds	 	26
	

SECTION 8. COLLATERAL AGENT	
 	

27
	

SECTION 9. CONTINUING SECURITY INTEREST; TRANSFER OF LOANS	
 	

27
	

SECTION 10. STANDARD OF CARE; COLLATERAL AGENT MAY PERFORM	
 	

27
	

SECTION 11. MISCELLANEOUS	
 	

27
	

Schedule 1    General Information	
 	

 
	

Schedule 2    Location of Equipment and Inventory	
 	

 
	

Schedule 3    Investment Related Property	
 	

 
	

Schedule 4    Description of Letters of Credit	
 	

 
	

Schedule 5    Intellectual Property and Exceptions	
 	

 
	

Schedule 6    Commercial Tort Claims	
 	

 
	

Exhibit A    Pledge Supplement	
 	

 

i

   
        This PLEDGE AND SECURITY AGREEMENT, dated as of June 30, 2004 (as amended, restated, supplemented or otherwise modified from time
to time this "Agreement"), is between EACH OF THE UNDERSIGNED, whether as an original signatory hereto
or as an Additional Grantor (as herein defined) (each, a "Grantor" and collectively, "Grantors"), and  CREDIT SUISSE FIRST BOSTON,
acting through its Cayman Islands Branch, as collateral agent for the Secured Parties (as herein defined) (in such capacity
as collateral agent, "Collateral Agent"). 

RECITALS:  

        WHEREAS, reference is made to that certain Credit and Guaranty Agreement, dated as of the date hereof (as it may
be amended, restated, supplemented or otherwise modified from time to time, the "Credit Agreement"), by and among MEDICAL DEVICE
MANUFACTURING, INC. ("Company"), UTI CORPORATION and the other Guarantors
party thereto, the lenders party thereto from time to time (the "Lenders"), CREDIT SUISSE FIRST BOSTON, acting through its
Cayman Islands Branch, as Lead Arranger, Administrative Agent and Collateral Agent, and the other agents party thereto; 

        WHEREAS, subject to the terms and conditions of the Credit Agreement, certain Grantors may enter into one or more Hedge Agreements with
one or more Lender Counterparties; 

        WHEREAS, in consideration of the extensions of credit and other accommodations of Lenders and Lender Counterparties as set forth in the
Credit Agreement and the Hedge Agreements, respectively, each Grantor has agreed to secure such Grantor's obligations under the Credit Documents and the Hedge Agreements as set forth herein; and 

        NOW, THEREFORE, in consideration of the premises and the agreements, provisions and covenants herein contained, each Grantor and
Collateral Agent agree as follows: 

SECTION 1. DEFINITIONS; GRANT OF SECURITY.  

        1.1    General Definitions.    In this Agreement, the following terms shall have the following meanings: 

        "Account Debtor" shall mean each Person who is obligated on a Receivable or any Supporting Obligation related thereto. 

        "Accounts" shall mean all "accounts" as defined in Article 9 of the UCC. 

        "Additional Grantors" shall have the meaning assigned in Section 5.2. 

        "Agreement" shall have the meaning set forth in the preamble. 

        "Assigned Agreements" shall mean all agreements and contracts to which such Grantor is a party as of the date hereof, or to which such
Grantor becomes a party after the date hereof, as each such agreement may be amended, restated, amended and restated, supplemented or otherwise modified from time to time. 

        "Cash Proceeds" shall have the meaning assigned in Section 7.7. 

        "Chattel Paper" shall mean all "chattel paper" as defined in Article 9 of the UCC, including, without limitation, "electronic
chattel paper" or "tangible chattel paper", as each term is defined in Article 9 of the UCC. 

        "Collateral" shall have the meaning assigned in Section 2.1. 

        "Collateral Agent" shall have the meaning set forth in the preamble. 

        "Collateral Records" shall mean books, records, ledger cards, files, correspondence, customer lists, blueprints, technical specifications,
manuals, computer software, computer printouts, tapes, disks and 

1

 

related
data processing software and similar items that at any time evidence or contain information relating to any of the Collateral or are otherwise necessary or helpful in the collection thereof or
realization thereupon. 

        "Collateral Support" shall mean all property (real or personal) assigned, hypothecated or otherwise securing any Collateral and shall
include any security agreement or other agreement granting a lien or security interest in such real or personal property. 

        "Commercial Tort Claims" shall mean all "commercial tort claims" as defined in Article 9 of the UCC, including, without limitation,
all commercial tort claims listed on Schedule 6 (as such schedule may be amended or supplemented from time to time). 

        "Commodities Accounts" (i) shall mean all "commodity accounts" as defined in Article 9 of the UCC and (ii) shall
include, without limitation, all of the accounts listed on Schedule 3 under the heading "Commodities Accounts" (as such schedule may be amended
or supplemented from time to time). 

        "Company" shall have the meaning set forth in the preamble. 

        "Concentration Account" means an Investment Account that in the ordinary course of business is not a zero-balance, controlled
disbursement, lock box or similar account, and into which funds from other Investment Accounts are transferred for the principal purpose of consolidating funds from such other Investment Accounts from
time to time in the ordinary course of business, whether by direct cash deposit, wire transfer, automated-clearing-house debit, or otherwise. 

        "Control Agreement" means, with respect to any Investment Related Property that is a "Deposit Account," an agreement in form and substance
reasonably satisfactory to Collateral Agent, pursuant to which Collateral Agent has "control" (within the meaning of Section 9-104 of the UCC) over such Deposit Account, and
(ii) with respect to any Investment Related Property consisting of Securities Accounts or Securities Entitlements, an agreement in form in form and substance reasonably satisfactory to
Collateral Agent pursuant to which the securities intermediary maintaining such Securities Account or Securities Entitlement has agreed to comply with Collateral Agent's "entitlement orders" without
further consent by any applicable Grantor or any other Person. 

        "Copyright Licenses" shall mean any and all agreements providing for the granting of any right in or to Copyrights (whether such Grantor
is licensee or licensor thereunder) including, without limitation, each agreement referred to in Schedule 5 (as such schedule may be amended or
supplemented from time to time). 

        "Copyrights" shall mean all United States and foreign copyrights, including but not limited to copyrights in software and databases, and
all Mask Works (as defined under 17 U.S.C. 901 of the U.S. Copyright Act), whether registered or unregistered, and, with respect to any and all of the foregoing: (i) all registrations and
applications therefor including, without limitation, the registrations and applications referred to in Schedule 5 (as such schedule may be
amended or supplemented from time to time), (ii) all extensions and renewals thereof, (iii) all rights corresponding thereto throughout the world, (iv) all rights to sue for past,
present and future infringements thereof, and (v) all Proceeds of the foregoing, including, without limitation, licenses, royalties, income, payments, claims, damages and proceeds of suit. 

        "Credit Agreement" shall have the meaning set forth in the recitals. 

        "Deposit Accounts" (i) shall mean all "deposit accounts" as defined in Article 9 of the UCC and (ii) shall include,
without limitation, all of the accounts listed on Schedule 3 under the heading "Deposit Accounts" (as such schedule may be amended or
supplemented from time to time). 

        "Documents" shall mean all "documents" as defined in Article 9 of the UCC. 

2

 

        "Equipment" shall mean: (i) all "equipment" as defined in Article 9 of the UCC, (ii) all machinery, manufacturing
equipment, data processing equipment, computers, office equipment, furnishings, furniture, appliances, fixtures and tools (in each case, regardless of whether characterized as equipment under the UCC)
and (iii) all accessions or additions thereto, all parts thereof, whether or not at any time of determination incorporated or installed therein or attached thereto, and all replacements
therefor, wherever located, now or hereafter existing, including any fixtures. 

        "General Intangibles" (i) shall mean all "general intangibles" as defined in Article 9 of the UCC, including "payment
intangibles" also as defined in Article 9 of the UCC and (ii) shall include, without limitation, all interest rate or currency protection or hedging arrangements, all tax refunds, all
licenses, permits, concessions and authorizations, all Assigned Agreements and all Intellectual Property (in each case, regardless of whether characterized as general intangibles under the UCC). 

        "Goods" (i) shall mean all "goods" as defined in Article 9 of the UCC and (ii) shall include, without limitation, all
Inventory and Equipment (in each case, regardless of whether characterized as goods under the UCC). 

        "Grantors" shall have the meaning set forth in the preamble. 

        "Indemnitee" shall mean Collateral Agent and its and its Affiliates' officers, partners, directors, trustees, employees, agents. 

        "Instruments" shall mean all "instruments" as defined in Article 9 of the UCC. 

        "Insurance" shall mean (i) all insurance policies covering any or all of the Collateral (regardless of whether Collateral Agent is
the loss payee thereof) and (ii) any key man life insurance policies. 

        "Intellectual Property" shall mean, collectively, the Copyrights, the Copyright Licenses, the Patents, the Patent Licenses, the
Trademarks, the Trademark Licenses, the Trade Secrets, and the Trade Secret Licenses. 

        "Inventory" shall mean (i) all "inventory" as defined in Article 9 of the UCC and (ii) all goods held for sale or
lease or to be furnished under contracts of service or so leased or furnished, all raw materials, work in process, finished goods, and materials used or consumed in the manufacture, packing, shipping,
advertising, selling, leasing, furnishing or production of such inventory or otherwise used or consumed in any Grantor's business; all goods in which any Grantor has an interest in mass or a joint or
other interest or right of any kind; and all goods which are returned to or repossessed by any Grantor, all computer programs embedded in any goods and all accessions thereto and products thereof (in
each case, regardless of whether characterized as inventory under the UCC). 

        "Investment Accounts" shall mean Securities Accounts, Commodities Accounts and Deposit Accounts. 

        "Investment Related Property" shall mean: (i) all "investment property" (as such term is defined in Article 9 of the UCC)
and (ii) all of the following (regardless of whether classified as investment property under the UCC): all Pledged Equity Interests, all Pledged Debt, the Investment Accounts and all
certificates of deposit. 

        "Lender" shall have the meaning set forth in the recitals. 

        "Letter of Credit Right" shall mean "letter-of-credit right" as defined in Article 9 of the UCC. 

        "Money" shall mean "money" as defined in the UCC. 

        "Patent Licenses" shall mean all agreements providing for the granting of any right in or to Patents (whether such Grantor is licensee or
licensor thereunder) including, without limitation, each agreement referred to in Schedule 5 (as such schedule may be amended or supplemented
from time to time). 

3

 

        "Patents" shall mean all United States and foreign patents and certificates of invention, or similar industrial property rights, and
applications for any of the foregoing, including, but not limited to: (i) each patent and patent application referred to in Schedule 5
hereto (as such schedule may be amended or supplemented from time to time), (ii) all reissues, divisions, continuations, continuations-in-part, extensions, renewals, and
reexaminations thereof, (iii) all rights corresponding thereto throughout the world, (iv) all inventions and improvements described therein, (v) all rights to sue for past,
present and future infringements thereof, (vi) all licenses, claims, damages, and proceeds of suit arising therefrom, and (vii) all Proceeds of the foregoing, including, without
limitation, licenses, royalties, income, payments, claims, damages, and proceeds of suit. 

        "Permitted Sale" shall mean those sales, transfers, dispositions or assignments permitted by the Credit Agreement. 

        "Pledge Supplement" shall mean any supplement to this Agreement in substantially the form of  Exhibit A. 

        "Pledged Debt" shall mean all Indebtedness owed to such Grantor, including, without limitation, all Indebtedness described on  Schedule 3 under the heading "Pledged
Debt" (as such schedule may be amended or supplemented from time to time), issued by the obligors named
therein, the instruments evidencing such Indebtedness, and all interest, cash, instruments and other property or proceeds from time to time received, receivable or otherwise distributed in respect of
or in exchange for any or all of such Indebtedness. 

        "Pledged Equity Interests" shall mean all Pledged Stock, Pledged LLC Interests, Pledged Partnership Interests and Pledged Trust Interests. 

        "Pledged LLC Interests" shall mean all interests in any limited liability company including, without limitation, all limited liability
company interests listed on Schedule 3 under the heading "Pledged LLC Interests" (as such schedule may be amended or supplemented from time to
time) and the certificates, if any, representing such limited liability company interests and any interest of such Grantor on the books and records of such limited liability company or on the books
and records of any securities intermediary pertaining to such interest and all dividends, distributions, cash, warrants, rights, options, instruments, securities and other property or proceeds from
time to time received, receivable or otherwise distributed in respect of or in exchange for any or all of such limited liability company interests. 

        "Pledged Partnership Interests" shall mean all interests in any general partnership, limited partnership, limited liability partnership or
other partnership including, without limitation, all partnership interests listed on Schedule 3 under the heading "Pledged Partnership Interests"
(as such schedule may be amended or supplemented from time to time) and the certificates, if any, representing such partnership interests and any interest of such Grantor on the books and records of
such partnership or on the books and records of any securities intermediary pertaining to such interest and all dividends, distributions, cash, warrants, rights, options, instruments, securities and
other property or proceeds from time to time received, receivable or otherwise distributed in respect of or in exchange for any or all of such partnership interests. 

        "Pledged Stock" shall mean all shares of capital stock owned by such Grantor, including, without limitation, all shares of capital stock
described on Schedule 3 under the heading "Pledged Stock" (as such schedule may be amended or supplemented from time to time), and the
certificates, if any, representing such shares and any interest of such Grantor in the entries on the books of the issuer of such shares or on the books of any securities intermediary pertaining to
such shares, and all dividends, distributions, cash, warrants, rights, options, instruments, securities and other property or proceeds from time to time received, receivable or otherwise distributed
in respect of or in exchange for any or all of such shares. 

4

 

        "Pledged Trust Interests" shall mean all interests in a Delaware business trust or other trust including, without limitation, all trust
interests listed on Schedule 3 under the heading "Pledged Trust Interests" (as such schedule may be amended or supplemented from time to time)
and the certificates, if any, representing such trust interests and any interest of such Grantor on the books and records of such trust or on the books and records of any securities intermediary
pertaining to such interest and all dividends, distributions, cash, warrants, rights, options, instruments, securities and other property or proceeds from time to time received, receivable or
otherwise distributed in respect of or in exchange for any or all of such trust interests. 

        "Proceeds" shall mean: (i) all "proceeds" as defined in Article 9 of the UCC, (ii) payments or distributions made
with respect to any Investment Related Property and (iii) whatever is receivable or received when Collateral or proceeds are sold, exchanged, collected or otherwise disposed of, whether such
disposition is voluntary or involuntary. 

        "Receivables" shall mean all rights to payment, whether or not earned by performance, for goods or other property sold, leased, licensed,
assigned or otherwise disposed of, or services rendered or to be rendered, including, without limitation all such rights constituting or evidenced by any Account, Chattel Paper, Instrument, General
Intangible or Investment Related Property, together with all of such Grantor's rights, if any, in any goods or other property giving rise to such right to payment and all Collateral Support and
Supporting Obligations related thereto and all Receivables Records. 

        "Receivables Records" shall mean (i) all original copies of all documents, instruments or other writings or electronic records or
other Records evidencing the Receivables, (ii) all books, correspondence, credit or other files, Records, ledger sheets or cards, invoices, and other papers relating to Receivables, including,
without limitation, all tapes, cards, computer tapes, computer discs, computer runs, record keeping systems and other papers and documents relating to the Receivables, whether in the possession or
under the control of such Grantor or any computer bureau or agent from time to time acting for such Grantor or otherwise, (iii) all evidences of the filing of financing statements and the
registration of other instruments in connection therewith, and amendments, supplements or other modifications thereto, notices to other creditors or secured parties, and certificates, acknowledgments,
or other writings, including, without limitation, lien search reports, from filing or other registration officers, (iv) all credit information, reports and memoranda relating thereto and
(v) all other written or nonwritten forms of information related in any way to the foregoing or any Receivable. 

        "Record" shall have the meaning specified in Article 9 of the UCC. 

        "Secured Obligations" shall have the meaning assigned in Section 3.1. 

        "Secured Parties" shall mean the Agents, the Lenders and the Lender Counterparties and shall include, without limitation, all former
Agents, Lenders and Lender Counterparties to the extent that any Obligations owing to such Persons were incurred while such Persons were Agents, Lenders or Lender Counterparties and such Obligations
have not been paid or satisfied in full. 

        "Securities" shall mean any stock, shares, partnership interests, voting trust certificates, certificates of interest or participation in
any profit-sharing agreement or arrangement, options, warrants, bonds, debentures, notes, or other evidences of indebtedness, secured or unsecured, convertible, subordinated or otherwise, or in
general any instruments commonly known as "securities" or any certificates of interest, shares or participations in temporary or interim certificates for the purchase or acquisition of, or any right
to subscribe to, purchase or acquire, any of the foregoing. 

        "Securities Accounts" (i) shall mean all "securities accounts" as defined in Article 8 of the UCC and (ii) shall
include, without limitation, all of the accounts listed on Schedule 3 under the heading "Securities Accounts" (as such schedule may be amended or
supplemented from time to time). 

5

 

        "Supporting Obligation" shall mean all "supporting obligations" as defined in Article 9 of the UCC. 

        "Trade Secret Licenses" shall mean any and all agreements providing for the granting of any right in or to Trade Secrets (whether such
Grantor is licensee or licensor thereunder) including, without limitation, each agreement referred to in Schedule 5 (as such schedule may be
amended or supplemented from time to time). 

        "Trade Secrets" shall mean all trade secrets and all other confidential or proprietary information and know-how whether or not
such Trade Secret has been reduced to a writing or other tangible form, including all documents and things embodying, incorporating, or referring in any way to such Trade Secret, including but not
limited to: (i) the right to sue for past, present and future misappropriation or other violation of any Trade Secret, and (ii) all Proceeds of the foregoing, including, without
limitation, licenses, royalties, income, payments, claims, damages, and proceeds of suit. 

        "Trademark Licenses" shall mean any and all agreements providing for the granting of any right in or to Trademarks (whether such Grantor
is licensee or licensor thereunder) including, without limitation, each agreement referred to in Schedule 5 (as such schedule may be amended or
supplemented from time to time). 

        "Trademarks" shall mean all United States and foreign trademarks, trade names, corporate names, company names, business names, fictitious
business names, Internet domain names, service marks, certification marks, collective marks, logos, other source or business identifiers, designs and general intangibles of a like nature, all
registrations and applications for any of the foregoing including, but not limited to: (i) the registrations and applications referred to in  Schedule 5 (as such schedule may be amended or
supplemented from time to time), (ii) all extensions or renewals of any of the foregoing,
(iii) all of the goodwill of the business connected with the use of and symbolized by the foregoing, (iv) the right to sue for past, present and future infringement or dilution of any of
the foregoing or for any injury to goodwill, and (v) all Proceeds of the foregoing, including, without limitation, licenses, royalties, income, payments, claims, damages, and proceeds of suit. 

        "UCC" shall mean the Uniform Commercial Code as in effect from time to time in the State of New York or, when the context implies, the
Uniform Commercial Code as in effect from time to time in any other applicable jurisdiction. 

        "United States" shall mean the United States of America. 

        1.2    Definitions; Interpretation.    All capitalized terms used herein (including the preamble and recitals hereto)
and not otherwise defined herein shall have the meanings ascribed thereto in the Credit Agreement or, if not defined therein, in the UCC. References to "Sections," "Exhibits" and "Schedules" shall be
to Sections, Exhibits and Schedules, as the case may be, of this Agreement unless otherwise specifically provided. Section headings in this Agreement are included herein for convenience of reference
only and shall not constitute a part of this Agreement for any other purpose or be given any substantive effect. Any of the terms defined herein may, unless the context otherwise requires, be used in
the singular or the plural, depending on the reference. The use herein of the word "include" or "including", when following any general statement, term or matter, shall not be construed to limit such
statement, term or matter to the specific items or matters set forth immediately following such word or to similar items or matters, whether or not nonlimiting language (such as "without limitation"
or "but not limited to" or words of similar import) is used with reference thereto, but rather shall be deemed to refer to all other items or matters that fall within the broadest possible scope of
such general statement, term or matter. If any conflict or inconsistency exists between this Agreement and the Credit Agreement, the Credit Agreement shall govern. All references herein to provisions
of the UCC shall include all successor provisions under any subsequent version or amendment to any Article of the UCC. 

6

 

SECTION 2. GRANT OF SECURITY.  

        2.1    Grant of Security.    Each Grantor hereby grants to Collateral Agent a security interest in and continuing lien
on all of such Grantor's right, title and interest in, to and under all personal property of such Grantor including, but not limited to the following, in each case whether now owned or existing or
hereafter acquired or arising and wherever located (all of which being hereinafter collectively referred to as the "Collateral"): 

        (a)   Accounts; 

        (b)   Chattel
Paper; 

        (c)   Documents; 

        (d)   General
Intangibles; 

        (e)   Goods;

        (f)    Instruments;

        (g)   Insurance;

        (h)   Intellectual
Property; 

        (i)    Investment
Related Property; 

        (j)    Letter
of Credit Rights; 

        (k)   Money;

        (l)    Receivables
and Receivable Records; 

        (m)  Commercial
Tort Claims; 

        (n)   to
the extent not otherwise included above, all Collateral Records, Collateral Support and Supporting Obligations relating to any of the foregoing; and 

        (o)   to
the extent not otherwise included above, all Proceeds, products, accessions, rents and profits of or in respect of any of the foregoing. 

        2.2    Certain Limited Exclusions.    Notwithstanding anything herein to the contrary, in no event shall the security
interest granted under Section 2.1 hereof attach to (a) any lease, license, contract, property rights or agreement to which any Grantor is
a party or any of its rights or interests thereunder if and for so long as the grant of such security interest shall constitute or result in (i) the abandonment, invalidation or
unenforceability of any right, title or interest of any Grantor therein or (ii) in a breach or termination pursuant to the terms of, or a default under, any such lease, license, contract
property rights or agreement (other than to the extent that any such term would be rendered ineffective pursuant to Sections 9-406, 9-407, 9-408 or
9-409 of the UCC (or any successor provision or provisions) of any relevant jurisdiction or any other applicable law (including the Bankruptcy Code) or principles of equity);  provided, however, that
such security interest shall attach immediately at such time as the condition causing such abandonment, invalidation or
unenforceability shall be remedied and to the extent severable, shall attach immediately to any portion of such lease, license, contract, property rights or agreement that does not result in any of
the consequences specified in clause (i) or (ii) above; or (b) any of the outstanding capital stock of a Foreign Subsidiary in excess of 65% of the voting power of all classes of
capital stock of such Foreign Subsidiary entitled to vote. 

SECTION 3. SECURITY FOR OBLIGATIONS; GRANTORS REMAIN LIABLE.  

        3.1    Security for Obligations.    This Agreement secures, and the Collateral is collateral security for, the prompt
and complete payment or performance in full when due, whether at stated maturity, by 

7

 

required
prepayment, declaration, acceleration, demand or otherwise (including the payment of amounts that would become due but for the operation of the automatic stay under Section 362(a) of
the Bankruptcy Code, 11 U.S.C. §362(a) (and any successor provision thereof)), of all Obligations with respect to every Grantor (the "Secured
Obligations"). 

        3.2    Continuing Liability Under Collateral.    Notwithstanding anything herein to the contrary, (a) each
Grantor shall remain liable for all obligations under the Collateral and nothing contained herein is intended or shall be a delegation of duties to Collateral Agent or any Secured Party,
(b) each Grantor shall remain liable under each of the agreements included in the Collateral, including, without limitation, any agreements relating to Pledged Partnership Interests or Pledged
LLC Interests, to perform all of the obligations undertaken by it thereunder all in accordance with and pursuant to the terms and provisions thereof and neither Collateral Agent nor any Secured Party
shall have any obligation or liability under any of such agreements by reason of or arising out of this Agreement or
any other document related thereto nor shall Collateral Agent nor any Secured Party have any obligation to make any inquiry as to the nature or sufficiency of any payment received by it or have any
obligation to take any action to collect or enforce any rights under any agreement included in the Collateral, including, without limitation, any agreements relating to Pledged Partnership Interests
or Pledged LLC Interests, and (c) the exercise by Collateral Agent of any of its rights hereunder shall not release any Grantor from any of its duties or obligations under the contracts and
agreements included in the Collateral. 

SECTION 4. REPRESENTATIONS AND WARRANTIES AND COVENANTS.  

        4.1    Generally.    

        (a)   Representations and Warranties.    Each Grantor hereby represents and warrants, on the Closing Date and on each
Credit Date, that: 

        (i)    it
owns the Collateral purported to be owned by it or otherwise has the rights it purports to have in each item of Collateral and, as to all Collateral whether now
existing or hereafter acquired, will continue to own or have such rights in each item of the Collateral (other than any Collateral sold, transferred, disposed or assigned in connection with a
Permitted Sale), in each case free and clear of any and all Liens, rights or claims of all other Persons, other than Permitted Liens; 

        (ii)   it
has indicated on Schedule 1 (as such schedule may be amended or supplemented from time to time) or, in the
case of any changes following the Closing Date, as otherwise notified to Collateral Agent in accordance with Section 5.1(j) of the Credit Agreement: (w) the type of organization of such
Grantor, (x) the jurisdiction of organization of such Grantor, (y) its organizational identification number and (z) the jurisdiction where its chief executive office or sole place
of business is, and for the one-year period preceding the date hereof has been, located; 

        (iii)  the
full legal name of such Grantor is as set forth on Schedule 1 and it has not done in the five years
preceding the Closing Date, and does not do, business under any other name (including any trade-name or fictitious business name) except for those names set forth on  Schedule 1 (as such schedule
may be amended or supplemented from time to time); 

        (iv)  except
as provided on Schedule 1, as of the Closing Date, it has not changed its name, jurisdiction of
organization, chief executive office or sole place of business or (except pursuant to the Acquisition) corporate structure in any way (e.g., by merger, consolidation, change in corporate form or
otherwise) within the five years preceding the Closing Date; 

        (v)   upon
the filing of all UCC financing statements naming each Grantor as "debtor" and Collateral Agent as "secured party" and describing the Collateral in the filing
offices set 

8

 

forth
opposite such Grantor's name on Schedule 1 hereof (as such schedule may be amended or supplemented from time to time) and upon execution of
a control agreement with respect to any Deposit Account, and, to the extent not subject to Article 9 of the UCC, upon recordation of the security interests granted hereunder in Patents,
Trademarks and Copyrights in the applicable intellectual property registries, including but not limited to the United States Patent and Trademark Office and the United States Copyright Office, the
security interests granted to Collateral Agent hereunder constitute valid and (except as otherwise permitted herein or in the Credit Agreement) perfected first priority Liens (subject in the case of
priority only to Permitted Liens) on all of the Collateral; 

        (vi)  to
the extent required by this Agreement, all actions and consents, including all filings, notices, registrations and recordings necessary or desirable for the exercise
by Collateral Agent of the voting or other rights provided for in this Agreement or the exercise of remedies in respect of the Collateral, have been made or obtained; 

        (vii) other
than the financing statements filed in favor of Collateral Agent, no effective UCC financing statement, fixture filing or other instrument similar in effect
under any applicable law covering all or any part of the Collateral is on file in any filing or recording office except for: (x) financing statements for which proper termination statements
have been delivered to Collateral Agent for filing, (y) financing statements in respect of which all Liens to which such financing statement relates have previously been discharged, and
(z) financing statements filed in connection with Permitted Liens; 

        (viii) no
authorization, approval or other action by, and no notice to or filing with, any Governmental Authority or regulatory body is required for either (y) the
pledge or grant by any Grantor of the Liens purported to be created in favor of Collateral Agent hereunder or (z) the exercise by Collateral Agent of any rights or remedies in respect of any
Collateral, except (A) for the filings contemplated by clause (v) above and (B) as may be required, in connection with the disposition of any Investment Related Property, by laws
generally affecting the offering and sale of Securities; 

        (ix)  none
of the Collateral constitutes, or is the Proceeds of, "farm products" (as defined in the UCC); 

        (x)   it
does not own any "as extracted collateral" (as defined in the UCC) or any timber to be cut; and 

        (xi)  as
of the Closing Date, such Grantor has been duly organized as an entity of the type as set forth opposite such Grantor's name on  Schedule 1 solely under the laws of the jurisdiction as set forth
opposite such Grantor's name on  Schedule 1 and remains duly existing as such. Except as otherwise notified to Collateral Agent in accordance with Section 5.1(j) of the
Credit Agreement, such Grantor has not filed any certificates of domestication, transfer or continuance in any other jurisdiction. 

        (b)   Covenants and Agreements.    Each Grantor hereby covenants and agrees that: 

        (i)    except
for the security interest created by this Agreement, it shall not create or suffer to exist any Lien upon or with respect to any of the Collateral (except
Permitted Liens), and such Grantor shall use commercially reasonable efforts to defend the Collateral against all Persons at any time claiming any interest therein; 

        (ii)   it
shall not produce, use or permit any Collateral to be used unlawfully or in violation of any provision of this Agreement or in material violation of any applicable
statute, regulation or ordinance or any policy of insurance covering the Collateral; 

9

 

        (iii)  except
on or prior to the Closing Date pursuant to the Acquisition, it shall not change such Grantor's name, identity, corporate structure (e.g., by merger,
consolidation, change in corporate form or otherwise) sole place of business, type of organization or jurisdiction of organization or establish any trade names unless it shall have complied with the
requirements of Section 5.1(j) of the Credit Agreement or otherwise notified Collateral Agent in writing by executing and delivering to Collateral Agent a completed Pledge Supplement,
substantially in the form of Exhibit A attached hereto, together with a supplement to  Schedule 1 hereto, prior to any such change or
establishment; and shall have, prior to any such change or establishment, taken all actions
necessary or reasonably requested by Collateral Agent to maintain the continuous validity, perfection and the same or better priority of Collateral Agent's security interest in the Collateral intended
to be granted and agreed to hereby; 

        (iv)  upon
such Grantor obtaining knowledge thereof, it shall promptly notify Collateral Agent in writing of any event that could reasonably be expected to have a Material
Adverse Effect on (x) the value of the Collateral, (y) the ability of any Grantor or Collateral Agent to dispose of the Collateral, or (z) the rights and remedies of Collateral
Agent in relation thereto, including, without limitation, the levy of any legal process against the Collateral or any material portion thereof; and 

        (v)   except
for Permitted Sales and Permitted Liens, it shall not take or permit any action which could reasonably be expected to materially impair Collateral Agent's rights
in the Collateral. 

        4.2    Equipment and Inventory.    

        (a)   Representations and Warranties.    Each Grantor represents and warrants, on the Closing Date and on each Credit
Date, that: 

        (i)    as
of the Closing Date, all of the Equipment and Inventory included in the Collateral is kept only at the locations specified in  Schedule 2 (as such schedule may be amended or supplemented from time
to time); and 

        (ii)   except
for Inventory or Equipment in respect of which the obligations under Section 4.2(b) have been satisfied,
none of the Inventory or Equipment is in the possession of an issuer of a negotiable document (as defined in Section 7-104 of the UCC) therefor or otherwise in the possession of a
bailee or a warehouseman. 

        (b)   Covenants and Agreements.    Each Grantor covenants and agrees that: 

        (i)    it
shall keep the Equipment, Inventory and any Documents evidencing any Equipment and Inventory in the locations specified on  Schedule 2 (as such schedule may be amended or supplemented from time to
time) unless it shall have taken all actions necessary or advisable to
maintain the continuous validity, perfection and the same or better priority of Collateral Agent's security interest in the Collateral intended to be granted and agreed to hereby, or to enable
Collateral Agent to exercise and enforce its rights and remedies hereunder, with respect to such Equipment and Inventory; 

        (ii)   it
shall keep records of the Inventory that are correct and accurate in all material respects and that are, in any event, in conformity with GAAP; 

        (iii)  it
shall not deliver any Document evidencing any Equipment and Inventory to any Person other than the issuer of such Document to claim the Goods evidenced therefor or
Collateral Agent; 

        (iv)  if
any Equipment or Inventory with an aggregate fair market value in excess of $1.0 million is in possession or control of any third party, each Grantor shall
notify Collateral 

10

 

Agent
and, if requested by Collateral Agent, join with Collateral Agent in notifying the third party of Collateral Agent's security interest and obtain an acknowledgment from the third party that it
is holding the Equipment and Inventory for the benefit of Collateral Agent; and 

        (v)   with
respect to any item of Equipment with a fair market value in excess of $100,000 individually or $1.0 million in the aggregate which is covered by a
certificate of title under a statute of any jurisdiction under the law of which indication of a security interest on such certificate is required as a condition of perfection thereof, upon the
reasonable request of Collateral Agent (not more frequently than once each calendar quarter so long as no Event of Default has occurred and is continuing), (x) provide information with respect
to any such Equipment, (y) execute and file with the registrar of motor vehicles or other appropriate authority in such jurisdiction an application or other document requesting the notation or
other indication of the security interest created hereunder on such certificate of title, and (z) deliver to Collateral Agent copies of all such applications or other documents filed during
such calendar quarter and copies of all such certificates of title issued during such calendar quarter indicating the security interest created hereunder in the items of Equipment covered thereby. 

        4.3    Receivables.    

        (a)   Representations and Warranties.    Each Grantor represents and warrants, on the Closing Date and on each Credit
Date, that: 

        (i)    each
Receivable (x) is and will be the legal, valid and binding obligation of the Account Debtor in respect thereof, representing an unsatisfied obligation of
such Account Debtor, (y) is and will be enforceable in accordance with its terms, and (z) is in compliance in all material respects with all applicable laws; 

        (ii)   none
of the Account Debtors in respect of any Receivable is the government of the United States, any agency or instrumentality thereof, any state or municipality or any
foreign sovereign. No Receivable requires the consent of the Account Debtor in respect thereof in connection with the pledge hereunder, except any consent which has been obtained or any requirement
that is not effective under the UCC; and 

        (iii)  no
Receivable is evidenced by, or constitutes, an Instrument or Chattel Paper which has not been delivered to, or otherwise subjected to the control of, Collateral
Agent to the extent required by and in accordance with Section 4.3(c). 

        (b)   Covenants and Agreements.    Each Grantor hereby covenants and agrees that: 

        (i)    it
shall keep and maintain at its own cost and expense true and complete records of the Receivables, including, but not limited to, records of all payments received and
all credits granted on the Receivables, all merchandise returned and all other dealings therewith; 

        (ii)   if
requested by Collateral Agent while an Event of Default is continuing, it shall mark conspicuously, in form and manner reasonably satisfactory to Collateral Agent,
all Chattel Paper, Instruments and other evidence of Receivables (other than any delivered to Collateral Agent as provided herein), as well as the Receivables Records with an appropriate reference to
the fact that Collateral Agent has a security interest therein; 

        (iii)  except
as could not reasonably be expected to have a Material Adverse Effect, it shall perform all of its obligations with respect to the Receivables; 

        (iv)  it
shall not amend, modify, terminate or waive any provision of any Receivable in any manner which could reasonably be expected to have a Material Adverse Effect. Other
than in the ordinary course of business as generally conducted by it on and prior to the date hereof, and except as otherwise provided in subsection (v) below, while an Event of Default is 

11

 

continuing,
such Grantor shall not (w) grant any extension or renewal of the time of payment of any Receivable, (x) compromise or settle any dispute, claim or legal proceeding with
respect to any Receivable for less than the total unpaid balance thereof, (y) release, wholly or partially, any Person liable for the payment thereof, or (z) allow any credit or discount
thereon; 

        (v)   except
as otherwise provided in this subsection, each Grantor shall continue to collect all amounts due or to become due to such Grantor under the Receivables and any
Supporting Obligation and diligently exercise each material right it may have under any Receivable any Supporting Obligation or Collateral Support, in each case, at its own expense and to the extent
advisable in its reasonable business judgment, and in connection with such collections and exercise, such Grantor shall take such action as such Grantor may deem necessary or advisable.
Notwithstanding the foregoing, Collateral Agent shall have the right at any time while an Event of Default is continuing to notify, or require any Grantor to notify, any Account Debtor of Collateral
Agent's security interest in the Receivables and any Supporting Obligation and, in addition, at any time following the occurrence and during the continuation of an Event of Default, Collateral Agent
may: (x) direct the Account Debtors under any Receivables to make payment of all amounts due or to become due to such Grantor thereunder directly to Collateral Agent; (y) notify, or
require any Grantor to notify, each Person maintaining a lockbox or similar arrangement to which Account Debtors under any Receivables have been directed to make payment to remit all amounts
representing collections on checks and other payment items from
time to time sent to or deposited in such lockbox or other arrangement directly to Collateral Agent; and (z) enforce, at the expense of such Grantor, collection of any such Receivables and to
adjust, settle or compromise the amount or payment thereof, in the same manner and to the same extent as such Grantor might have done. If Collateral Agent notifies any Grantor that it has elected to
collect the Receivables in accordance with the preceding sentence, any payments of Receivables received by such Grantor shall be forthwith (and in any event within two Business Days) deposited by such
Grantor in the exact form received, duly indorsed by such Grantor to Collateral Agent if required, in a collateral account maintained under the sole dominion and control of Collateral Agent, and until
so turned over, all amounts and proceeds (including checks and other instruments) received by such Grantor in respect of the Receivables, any Supporting Obligation or Collateral Support shall be
received in trust for the benefit of Collateral Agent hereunder and shall be segregated from other funds of such Grantor and such Grantor shall not adjust, settle or compromise the amount or payment
of any Receivable, or release wholly or partly any Account Debtor or obligor thereof, or allow any credit or discount thereon; and 

        (vi)  it
shall use commercially reasonable efforts to keep in full force and effect any Supporting Obligation or Collateral Support relating to any Receivable to the extent
advisable in its reasonable business judgment. 

        (c)   Delivery and Control of Receivables.    With respect to any Receivables in excess of $500,000 individually or
$1.0 million in the aggregate that are evidenced by, or constitute, Chattel Paper or Instruments, each Grantor shall notify Collateral Agent of such fact and, if requested by Collateral Agent,
cause each originally executed copy thereof to be delivered to Collateral Agent (or its agent or designee) appropriately indorsed to Collateral Agent or indorsed in blank: (i) with respect to
any such Receivables in existence on the date hereof, on or prior to the date hereof, and (ii) with respect to any such Receivables hereafter arising, no later than the next following date on
which reports are delivered pursuant to Section 5.1(b) of the Credit Agreement. With respect to any Receivables in excess of $500,000 individually or $1.0 million in the aggregate which
would constitute "electronic chattel paper" under Article 9 of the UCC, each Grantor shall notify Collateral Agent of such fact and, if requested by Collateral Agent, shall take all steps
necessary to 

12

 

give
Collateral Agent control over such Receivables (within the meaning of Section 9-105 of the UCC): (i) with respect to any such Receivables in existence on the date
hereof, on or prior to the date hereof, and (ii) with respect to any such Receivables hereafter arising, within ten days of such Grantor acquiring rights therein. Any Receivable not otherwise
required to be delivered or subjected to the control of Collateral Agent in accordance with this subsection (c) shall be delivered or subjected to such control upon the reasonable request of
Collateral Agent. 

        4.4    Investment Related Property.    

        4.4.1 Investment Related Property Generally

        (a)   Covenants and Agreements.    Each Grantor hereby covenants and agrees that: 

        (i)    in
the event it acquires rights in any Investment Related Property after the date hereof, it shall deliver to Collateral Agent (in the case of any Investment Related
Property subject to the requirements of Section 5.10 of the Credit Agreement, within the time periods set forth therein) a completed Pledge Supplement, substantially in the form of  Exhibit A
attached hereto, together with all supplements to Schedules thereto, reflecting such new Investment Related Property. Notwithstanding
the foregoing, it is understood and agreed that the security interest of Collateral Agent shall attach to all Investment Related Property immediately upon any Grantor's acquisition of rights therein
and shall not be affected by the failure of any Grantor to deliver a supplement to Schedule 3 as required hereby; 

        (ii)   except
as provided in the next sentence, in the event such Grantor receives any dividends, interest or distributions on any Investment Related Property, or any
securities or other property upon the merger, consolidation, liquidation or dissolution of any issuer of any Investment Related Property, then (y) such dividends, interest or distributions and
securities or other property shall be included in the definition of Collateral without further action and (z) such Grantor shall promptly take all steps, if any, necessary or advisable to
ensure the validity, perfection, priority and, if applicable, control of Collateral Agent over such Investment Related Property (including, without limitation, delivery thereof to Collateral Agent)
and pending any such action such Grantor shall be deemed to hold such dividends, interest, distributions, securities or other property in trust for the benefit of Collateral Agent and shall segregate
such dividends, distributions, Securities or other property from all other property of such Grantor. Notwithstanding the foregoing, so long as no Event of Default shall have occurred and be
continuing, Collateral Agent authorizes each Grantor to retain all cash dividends and distributions and all scheduled payments of principal and interest, in each case to the extent such dividends,
distributions and scheduled payments are permitted under the Credit Agreement; and 

        (iii)  each
Grantor consents to the grant by each other Grantor of a Security Interest in all Investment Related Property to Collateral Agent. 

        (b)   Delivery and Control. 

Each
Grantor agrees that, except as otherwise permitted herein or in the Credit Agreement, with respect to any Investment Related Property in which it currently has rights it shall comply with the
provisions of this Section 4.4.1(b) on or before the Credit Date and with respect to any Investment Related Property hereafter acquired by such
Grantor it shall comply with the provisions of this Section 4.4.1(b) immediately upon acquiring rights therein, in each case in form and
substance reasonably satisfactory to Collateral Agent; provided that (i) Grantors shall not be required to comply with the provisions of this  Section 4.4.1(b)
 with respect to the capital stock of Venusa de Mexico, 

13

 

S.A.
de C.V., Star Guide, Ltd or Medis S.A. de C.V. until the date that is 30 days after the Closing Date, (ii) Grantors shall only be required to deliver certificate(s)
evidencing 50% of the capital stock of Star Guide, Ltd. (indorsed as required below) until the date that is six months after the Closing Date, and (iii) Grantors shall not be required to
deliver evidence of the pledge under German law of 65% of the equity interests in UTISFM Feinmechanik GmbH, a German limited liability company, until the date that is the earlier of (A) the
first anniversary of the Closing Date and (B) 60 days after a determination by Grantors not to actively pursue the sale of UTISFM Feinmechanik GmbH or substantially all its assets. With
respect to any Investment Related Property that is represented by a certificate or that is an "instrument" (other than any Investment Related Property credited to a Securities Account) it shall cause
such certificate or instrument to be delivered to Collateral Agent, indorsed in blank by an "effective indorsement" (as defined in Section 8-107 of the UCC), regardless of whether
such certificate constitutes a "certificated security" for purposes of the UCC. With respect to any Investment Related Property that is an "uncertificated security" for purposes of the UCC (other than
any "uncertificated securities" credited to a Securities Account), it shall cause the issuer of such uncertificated security to either (i) register Collateral Agent as the registered owner
thereof on the books and records of the issuer or (ii) execute an agreement in form and substance reasonably satisfactory to Collateral Agent, pursuant to which such issuer agrees to comply
with Collateral Agent's instructions with respect to such uncertificated security without further consent by such Grantor. 

        (c)   Voting and Distributions. 

        (i)    So
long as no Event of Default shall have occurred and be continuing: 

        (1)   except
as otherwise provided under the covenants and agreements relating to investment related property in this Agreement or elsewhere herein or in the Credit Agreement,
each Grantor shall be entitled to exercise or refrain from exercising any and all voting and other consensual rights pertaining to the Investment Related Property or any part thereof for any purpose
not inconsistent with the terms of this Agreement or the Credit Agreement; and 

        (2)   Collateral
Agent shall promptly execute and deliver (or cause to be executed and delivered) to each Grantor all proxies, and other instruments as such Grantor may from
time to time reasonably request for the purpose of enabling such Grantor to exercise the voting and other consensual rights when and to the extent which it is entitled to exercise pursuant to
clause (1) above. 

        (ii)   Upon
the occurrence and during the continuation of an Event of Default: 

        (1)   all
rights of each Grantor to exercise or refrain from exercising the voting and other consensual rights which it would otherwise be entitled to exercise pursuant hereto
shall cease and all such rights shall thereupon become vested in Collateral Agent who shall thereupon have the sole right to exercise such voting and other consensual rights; and 

        (2)   in
order to permit Collateral Agent to exercise the voting and other consensual rights which it may be entitled to exercise pursuant hereto and to receive all dividends
and other distributions which it may be entitled to receive hereunder: (y) each Grantor shall promptly execute and deliver (or cause to be executed and delivered) to Collateral Agent all
proxies, dividend payment orders and other instruments as Collateral Agent may from time to time reasonably request and (z) each Grantor acknowledges that Collateral Agent may utilize the
power of attorney set forth in Section 6.1. 

14

  

        4.4.2 Pledged Equity Interests

        (a)   Representations and Warranties.    Each Grantor hereby represents and warrants, on the Closing Date and on each
Credit Date, that: 

        (i)    Schedule 3 (as such schedule may be amended or supplemented from time to time) sets forth under the headings
"Pledged Stock, "Pledged LLC Interests," "Pledged Partnership Interests" and "Pledged Trust Interests," respectively, all of the Pledged Stock, Pledged LLC Interests, Pledged Partnership Interests and
Pledged Trust Interests owned by any Grantor as of the Closing Date and as of each date that a Pledge Supplement is required to be delivered pursuant to  Section 4.4.1(a) and such Pledged Equity
Interests constitute the percentage of issued and outstanding shares of stock, percentage of membership
interests, percentage of partnership interests or percentage of beneficial interest of the respective issuers thereof indicated on such Schedule; 

        (ii)   except
in connection with any Permitted Sale, it is the record and beneficial owner of the Pledged Equity Interests free of all Liens (other than Permitted Liens of a
nonconsensual nature that apply to the applicable Grantor's assets generally), rights or claims of other Persons and, except as set forth on  Schedule 3, there are no outstanding warrants, options
or other rights to purchase, or shareholder, voting trust or similar agreements
outstanding with respect to, or property that is convertible into, or that requires the issuance or sale of, any Pledged Equity Interests; 

        (iii)  none
of the Pledged LLC Interests nor Pledged Partnership Interests are or represent interests in issuers that are registered as investment companies or are dealt in
or traded on securities exchanges or markets; and 

        (iv)  as
of the Closing Date, except as set forth on Schedule 3, all of the Pledged LLC Interests and Pledged
Partnership Interests are or represent interests in issuers that have opted to be treated as securities under the uniform commercial code of any jurisdiction. 

        (b)   Covenants and Agreements.    Each Grantor hereby covenants and agrees that: 

        (i)    without
the prior written consent of Collateral Agent, it shall not vote to enable or take any other action to: (A) other than in connection with a Permitted
Sale, permit any issuer of any Pledged Equity Interest to issue to any Person other than a Grantor any additional stock, partnership interests, limited liability company interests or other equity
interests of any nature or to issue securities convertible into or granting the right of purchase or exchange for any stock or other equity interest of any nature of such issuer, or (B) cause
any issuer of any Pledged Partnership Interests or Pledged LLC Interests which are not securities (for purposes of the UCC) on the date hereof to elect or otherwise take any action to cause such
Pledged Partnership Interests or Pledged LLC Interests to be treated as securities for purposes of the UCC; provided,  however, notwithstanding the
foregoing, if any issuer of any Pledged Partnership Interests or Pledged LLC Interests takes any such action in violation
of the foregoing in this clause (B), such Grantor shall promptly notify Collateral Agent in writing of any such election or action and, in such event, shall take all steps necessary or
advisable to establish Collateral Agent's "control" thereof; 

        (ii)   it
shall comply in all material respects with all of its obligations under any partnership agreement or limited liability company agreement relating to Pledged
Partnership Interests or Pledged LLC Interests and shall enforce all of its rights with respect to any Investment Related Property; and 

15

 

        (iii)  each
Grantor consents to the grant by each other Grantor of a security interest in all Investment Related Property to Collateral Agent and, without limiting the
foregoing, consents to the transfer of any Pledged Partnership Interest and any Pledged LLC Interest to Collateral Agent or its nominee following an Event of Default and to the substitution of
Collateral Agent or its nominee as a partner in any partnership or as a member in any limited liability company with all the rights and powers related thereto. 

        4.4.3 Pledged Debt

        (a)   Representations and Warranties.    Each Grantor hereby represents and warrants, on the Closing Date and each
Credit Date, that Schedule 3 (as such schedule may be amended or supplemented from time to time) sets forth under the heading "Pledged Debt" all
of the Pledged Debt evidenced by Chattel Paper or Instruments owned by any Grantor as of the Closing Date and (other than outstanding intercompany Indebtedness permitted by and incurred in accordance
with Section 6.1(b) of the Credit Agreement) as of each date that reports are delivered pursuant to Section 5.1(b) of the Credit Agreement. 

        (b)   Covenants and Agreements.    Each Grantor hereby covenants and agrees that it shall notify Collateral Agent of
any default under any Pledged Debt that has caused, either in any individual case or in the aggregate, a Material Adverse Effect. 

        4.4.4 Investment Accounts

        (a)   Representations and Warranties.    Each Grantor hereby represents and warrants, on the Closing Date and each
Credit Date, that: 

        (i)    Schedule 3 hereto (as such schedule may be amended or supplemented from time to time) sets forth under the
headings "Securities Accounts" and "Commodities Accounts," respectively, all of the Securities Accounts and Commodities Accounts in which each Grantor has an interest. Each Grantor, as applicable, is
the sole entitlement holder of each such Securities Account and Commodity Account, and such Grantor has not consented to, and is not otherwise aware of, any Person (other than Collateral Agent
pursuant thereto) having "control" (within the meanings of Sections 8-106 and 9-106 of the UCC) over, or any other interest in, any such Securities Account or Commodity Account
or securities or other property credited thereto that remains effective as of or at any time following the Closing Date; 

        (ii)   Schedule 3 hereto (as such schedule may be amended or supplemented from time to time) sets forth under the
headings "Deposit Accounts" all of the Deposit Accounts in which each Grantor has an interest. Each Grantor, as applicable, is the sole account holder of each such Deposit Account and such Grantor has
not consented to, and is not otherwise aware of, any Person (other than Collateral Agent pursuant thereto) having either sole dominion and control (within the meaning of common law) or "control"
(within the meanings of Section 9-104 of the UCC) over, or any other interest in, any such Deposit Account or any money or other property deposited therein that remains effective as
of or at any time following the Closing Date; and 

        (iii)  to
the extent required under Section 4.4.4(c), each Grantor has taken all actions necessary to:
(x) establish Collateral Agent's "control" (within the meanings of Sections 8-106 and 9-106 of the UCC) over any portion of the Investment Related Property constituting
Securities Accounts, Securities Entitlements or Commodities Accounts (each as defined in the UCC); and (y) establish Collateral Agent's "control" (within the meaning of
Section 9-104 of the UCC) over all Deposit Accounts. 

16

 

        (b)   Covenant and Agreement.    Each Grantor hereby covenants and agrees with the Collateral Agent and each other
Secured Party that it shall not close or terminate any Investment Account unless a successor or replacement account has been established with respect to which successor or replacement account a
control agreement has been entered into by the appropriate Grantor, Collateral Agent and the securities intermediary or depository institution at which such successor or replacement account is to be
maintained in accordance with the provisions of Section 4.4.4(c). 

        (c)   Delivery and Control

        (i)    For
each Concentration Account set forth on Schedule 3, or that any Grantor at any time opens or maintains, such
Grantor shall (A) enter into and maintain a Control Agreement covering such Concentration Account, or (B) close such Concentration Account and transfer the assets held in such
Concentration Account to a Concentration Account that is subject to a Control Agreement. Such Grantor shall promptly notify Collateral Agent of the opening of any new Concentration Account.
Furthermore, each Grantor covenants and agrees that it shall (x) deposit all collected amounts into its existing Investment Accounts or such other Investment Accounts as it shall from time to
time establish and maintain, and (y) sweep all such deposited amounts, on a daily basis, into one or more Concentration Accounts. Each Grantor further agrees that it shall not maintain any cash
or other balances in any Investment Account that is not a Concentration Account except in (A) Investment Accounts the balances of which are swept into one or more Concentration Accounts as
provided in clauses (x) and (y) of the immediately preceding sentence or (B) an Investment Account that is subject to a Control Agreement. Each applicable Grantor shall have
entered into a Control Agreement with respect to each Concentration Account that exists on the Closing Date, as of or prior to the Closing Date. Notwithstanding the foregoing, in respect of those
Investment Accounts set forth on Schedule 3 that are not subject to a Control Agreement as of the Closing Date (other than any Concentration
Account that exists on the Closing Date, which shall be subject to the requirements of the immediately preceding sentence), no later than 30 days after the Closing Date (or such later date as
consented to by Collateral Agent) such Grantor shall either (i) enter into a Control Agreement covering such Investment Account or (ii) close such Investment Account and transfer the
assets held in such Investment Account to an Investment Account that is subject to a Control Agreement. 

        (ii)   Upon
the occurrence and during the continuation of an Event of Default, Collateral Agent shall have the right, without notice to any Grantor, to transfer all or any
portion of the Investment Related Property to its name or the name of its nominee or agent. In addition, Collateral Agent shall have the right at any time, without notice to any Grantor, to exchange
any certificates or instruments representing any Investment Related Property for certificates or instruments of smaller or larger denominations. 

        (iii)  Collateral
Agent agrees that, so long as no Event of Default shall have occurred and be continuing, it shall not deliver any notice of sole control, direction to
transfer funds, money or investments, direction to limit the access of any Grantor to any funds, money or investments or similar directions in respect of any Investment Account or Investment Related
Property. 

        4.5    Letter of Credit Rights.    

        (a)   Representations and Warranties.    Each Grantor hereby represents and warrants, on the Closing Date and on each
Credit Date, that: (i) all material letters of credit to which such Grantor has rights as of the Closing Date and as of each date that reports are required to be delivered pursuant to
Section 5.1(b) of the Credit Agreement is listed on Schedule 4 (as such schedule may 

17

 

be
amended or supplemented from time to time) hereto; and (ii) to the extent required by the Collateral Agent, it has obtained the consent of each issuer of any material letter of credit to the
assignment of the proceeds of the letter of credit to Collateral Agent. 

        (b)   Covenants and Agreements.    Each Grantor hereby covenants and agrees that with respect to any material letter
of credit hereafter arising it shall, if requested by the Collateral Agent, obtain the consent of the issuer thereof to the assignment of the proceeds of the letter of credit to Collateral Agent and
shall deliver to Collateral Agent a completed Pledge Supplement, substantially in the form of Exhibit A attached hereto, together with a
supplement to Schedule 4 hereto. 

        4.6    Intellectual Property.    

        (a)   Representations and Warranties.    Except as disclosed in  Schedule 5 (as such schedule may be amended or supplemented from time to time), each
Grantor hereby represents and warrants, on the Closing Date
and on each Credit Date, that: 

        (i)    Schedule 5 (as such schedule may be amended or supplemented from time to time) sets forth, as of the Closing Date
and as of each date that Schedule 5 is required to be updated pursuant to  Section 4.6(b)(vii), a true and complete list of (y) all United
States, state and foreign registrations of and applications for Patents,
Trademarks, and Copyrights owned by each Grantor and (z) all Patent Licenses, Trademark Licenses, Trade Secret Licenses and Copyright Licenses (other than off-the-shelf
software) of such Grantor; 

        (ii)   as
of the Closing Date and as of each date that Schedule 5 is required to be updated pursuant to  Section 4.6(b)(vii), it is the sole and exclusive
owner of the entire right, title, and interest in and to all Intellectual Property listed on  Schedule 5 (as such schedule may be amended or supplemented from time to time), and owns or has the
valid right to use all other Intellectual
Property material to the conduct its business, free and clear of all Liens, claims, encumbrances and licenses, except in each case for Permitted Liens and the licenses set forth on  Schedule 5 (as
such schedule may be amended or supplemented from time to time) or otherwise permitted pursuant to a Permitted Sale; 

        (iii)  except
as could not reasonably be expected to have a Material Adverse Effect, (x) all Intellectual Property is subsisting and has not been adjudged invalid or
unenforceable, in whole or in part, and (y) each Grantor has performed all acts and has paid all renewal, maintenance, and other fees and taxes
required to maintain each and every registration and application of Copyrights, Patents and Trademarks in full force and effect; 

        (iv)  except
as could not reasonably be expected to have a Material Adverse Effect, (x) all Intellectual Property is valid and enforceable; and (y) no holding,
decision, or judgment has been rendered in any action or proceeding before any court or administrative authority challenging the validity of, such Grantor's right to register, or such Grantor's rights
to own or use, any Intellectual Property and no such action or proceeding is pending or, to the best of such Grantor's knowledge, threatened; 

        (v)   all
registrations and applications for Copyrights, Patents and Trademarks material to the conduct of Grantors' business are standing in the name of one or more Grantors,
and, except in the ordinary course of business and as permitted under the Credit Agreement, none of the Trademarks, Patents or Copyrights has been licensed by any Grantor to any Affiliate or third
party (other than a Grantor), except as disclosed in Schedule 5 (as such schedule may be amended or supplemented from time to time); 

        (vi)  except
as could not reasonably be expected to have a Material Adverse Effect, (x) the conduct of Grantors' business does not infringe upon or otherwise violate
any trademark, patent, copyright, trade secret or other intellectual property right owned or 

18

 

controlled
by a third party, and (y) no claim has been made that the use of any Intellectual Property owned or used by Grantor (or any of its respective licensees) violates the asserted rights
of any third party; 

        (vii) to
the best of each Grantor's knowledge, except as could not reasonably be expected to have a Material Adverse Effect, no third party is infringing upon or otherwise
violating any rights in any Intellectual Property owned or used by such Grantor, or any of its respective licensees; and 

        (viii) except
for license agreements permitted by the Credit Agreement and Permitted Sales, no Grantor has made a previous assignment, sale, transfer or agreement
constituting a present or future assignment, sale or transfer of any Intellectual Property that has not been terminated or released. 

        (b)   Covenants and Agreements.    Each Grantor hereby covenants and agrees as follows: 

        (i)    except
for Permitted Sales, it shall not do any act or omit to do any act whereby any of the Intellectual Property which is material to the business of Grantor may
lapse, or become abandoned,
dedicated to the public, or unenforceable, or which would adversely affect the validity, grant, or enforceability of the security interest granted therein; 

        (ii)   except
for Permitted Sales and except as may otherwise be commercially reasonable, it shall not, with respect to any Trademarks which are material to the business of
any Grantor, cease the use of any of such Trademarks or fail to maintain the level of the quality of products sold and services rendered under any of such Trademark at a level at least substantially
consistent with the quality of such products and services as of the date hereof, and each Grantor shall use commercially reasonable efforts to insure that licensees of such Trademarks use such
consistent standards of quality; 

        (iii)  it
shall, within thirty days of the creation or acquisition of any copyrightable work which is material to the business of Grantor, apply to register the Copyright in
the United States Copyright Office; 

        (iv)  it
shall, not later than the next following date upon which reports are required to be delivered pursuant to Section 5.1(b) of the Credit Agreement, notify
Collateral Agent if it knows or has reason to know that any item of the Intellectual Property that is material to the business of any Grantor may become (x) abandoned or dedicated to the public
or placed in the public domain, (y) invalid or unenforceable, or (z) subject to any adverse determination or development (including the institution of proceedings) in any action or
proceeding in the United States Patent and Trademark Office, the United States Copyright Office, any state registry, any foreign counterpart of the foregoing, or any court; 

        (v)   it
shall take all reasonable steps in the United States Patent and Trademark Office, the United States Copyright Office, any state registry or (with respect to any item
of Intellectual Property that is material to the conduct of Grantors' business) any foreign counterpart of the foregoing, to pursue any application and maintain any registration of each Trademark,
Patent, and Copyright owned by any Grantor and material to its business which is now or shall become included in the Intellectual Property including, but not limited to, those items on  Schedule 5
(as such schedule may be amended or supplemented from time to time); 

        (vi)  in
the event that any material Intellectual Property owned by or exclusively licensed to any Grantor is infringed, misappropriated, or diluted by a third party, such
Grantor shall promptly take all actions appropriate in its reasonable business judgment to stop such infringement, misappropriation, or dilution and protect its rights in such Intellectual Property
including, if appropriate, the initiation of a suit for injunctive relief and to recover damages; 

19

 

        (vii) it
shall, not later than the next following date upon which reports are required to be delivered pursuant to Section 5.1(b) of the Credit Agreement, promptly
(but in no event more than thirty days
after any Grantor obtains knowledge thereof) report to Collateral Agent: (y) the filing of any application to register any Intellectual Property owned by such Grantor with the United States
Patent and Trademark Office, the United States Copyright Office, or any state registry or (with respect to any item of Intellectual Property that is material to the conduct of the Grantors' business)
foreign counterpart of the foregoing (whether such application is filed by such Grantor or through any agent, employee, licensee, or designee thereof) and (z) the registration of any such
Intellectual Property by any such office, in each case by executing and delivering to Collateral Agent a completed Pledge Supplement, substantially in the form of  Exhibit A attached hereto,
together with a supplement to Schedule 5 hereto; and 

        (viii) it
shall, promptly upon the reasonable request of Collateral Agent, execute and deliver to Collateral Agent any document required to acknowledge, confirm, register,
record, or perfect Collateral Agent's interest in any part of the Intellectual Property, whether now owned or hereafter acquired. 

        4.7    Commercial Tort Claims.    

        (a)   Representations and Warranties.    Each Grantor hereby represents and warrants, on the Closing Date and on each
Credit Date, that Schedule 6 (as such schedule may be amended or supplemented from time to time), as of the Closing Date and as of each date that  Schedule 6 is required to be updated pursuant to Section 4.7(b), sets forth all Commercial
Tort Claims of the Grantors in excess of $500,000 individually or $1.0 million in the aggregate. 

        (b)   Covenants and Agreements.    Each Grantor hereby covenants and agrees that with respect to any Commercial Tort
Claim in excess of $500,000 individually or $1.0 million in the aggregate hereafter arising it shall, the next following date upon which reports are required to be delivered pursuant to
Section 5.1(b) of the Credit Agreement, deliver to Collateral Agent a completed Pledge Supplement, substantially in the form of Exhibit A
attached hereto, together with a supplement to Schedule 6 hereto, identifying such new Commercial Tort Claims. 

SECTION 5. FURTHER ASSURANCES; ADDITIONAL GRANTORS.  

        5.1    Further Assurances.    

        (a)   Each
Grantor agrees that from time to time, at the expense of such Grantor, that it shall promptly execute and deliver all further instruments and documents, and take
all further action, that may be
necessary or desirable, or that Collateral Agent may reasonably request, in order to create and/or maintain the validity, perfection or priority of and protect any security interest granted hereby or
to enable Collateral Agent to exercise and enforce its rights and remedies hereunder with respect to any Collateral, in each case to the extent required hereunder. Without limiting the generality of
the foregoing, each Grantor shall: 

        (i)    file
such financing or continuation statements, or amendments thereto, and execute and deliver such other agreements, instruments, endorsements, powers of attorney or
notices, as may be necessary or desirable, or as Collateral Agent may reasonably request, in order to perfect and preserve the security interests granted or purported to be granted hereby; 

        (ii)   take
all actions necessary to ensure the recordation of appropriate evidence of the liens and security interest granted hereunder in the Intellectual Property with any
intellectual property registry in which said Intellectual Property is registered or in which an application for registration is pending including, without limitation, the United States Patent and
Trademark 

20

 

Office,
the United States Copyright Office, the various Secretaries of State, and (with respect to any item of Intellectual Property that is material to the conduct of the Grantors' business) the
foreign counterparts on any of the foregoing; 

        (iii)  subject
to Section 5.6 of the Credit Agreement, at any reasonable time, upon request by Collateral Agent, allow inspection of the Collateral by Collateral Agent
or persons designated by Collateral Agent; and 

        (iv)  at
Collateral Agent's request, appear in and defend any action or proceeding that may affect such Grantor's title to or Collateral Agent's security interest in all or
any part of the Collateral. 

        (b)   Each
Grantor hereby authorizes Collateral Agent to file a Record or Records, including, without limitation, financing or continuation statements, and amendments
thereto, in any jurisdictions and with any filing offices as Collateral Agent may determine, in its sole discretion, are necessary or advisable to perfect the security interest granted to Collateral
Agent herein. Such financing statements may describe the Collateral in the same manner as described herein or may contain an indication or description of collateral that describes such property in any
other manner as Collateral Agent may determine, in its sole discretion, is necessary, advisable or prudent to ensure the perfection of the security interest in the Collateral granted to Collateral
Agent herein, including, without limitation, describing such property as "all assets" or "all personal property, whether now owned or hereafter acquired." Each Grantor shall furnish to Collateral
Agent from time to time statements and schedules further identifying and describing the Collateral and such other reports in connection with the Collateral as Collateral Agent may reasonably request,
all in reasonable detail. 

        (c)   Each
Grantor hereby authorizes Collateral Agent to modify this Agreement after obtaining such Grantor's approval of or signature to such modification by amending  Schedule 5 (as such schedule may be
amended or supplemented from time to time) to include reference to any right, title or interest in any
existing Intellectual Property or any Intellectual Property acquired or developed by any Grantor after the execution hereof or to delete any reference to any right, title or interest in any
Intellectual Property in which any Grantor no longer has or claims any right, title or interest. 

        5.2    Additional Grantors.    From time to time subsequent to the date hereof, additional Persons may become parties
hereto as additional Grantors (each, an "Additional Grantor") by executing a Counterpart Agreement. Upon delivery of any such Counterpart Agreement to
Collateral Agent, notice of which is hereby waived by Grantors, each Additional Grantor shall be a Grantor and shall be as fully a party hereto as if Additional Grantor were an original signatory
hereto. Each Grantor expressly agrees that its obligations arising hereunder shall not be affected or diminished by the addition or release of any other Grantor hereunder. This Agreement shall be
fully effective as to any Grantor that is or becomes a party hereto regardless of whether any other Person becomes or fails to become or ceases to be a Grantor hereunder. 

SECTION 6. COLLATERAL AGENT APPOINTED ATTORNEY-IN-FACT.  

        6.1    Power of Attorney.    Each Grantor hereby irrevocably appoints Collateral Agent (such appointment being coupled
with an interest) as such Grantor's attorney-in-fact, with full authority in the place and stead of such Grantor and in the name of such Grantor, Collateral Agent or otherwise,
from time to time in Collateral Agent's discretion to take any action and to execute any instrument 

21

 

that
Collateral Agent may deem reasonably necessary or advisable to accomplish the purposes of this Agreement, including, without limitation, the following: 

        (a)   upon
the occurrence and during the continuance of any Event of Default, to obtain and adjust insurance required to be maintained by such Grantor or paid to Collateral
Agent pursuant to the Credit Agreement; 

        (b)   upon
the occurrence and during the continuance of any Event of Default, to ask for, demand, collect, sue for, recover, compound, receive and give acquittance and
receipts for moneys due and to become due under or in respect of any of the Collateral; 

        (c)   upon
the occurrence and during the continuance of any Event of Default, to receive, endorse and collect any drafts or other instruments, documents and chattel paper in
connection with clause (b) above; 

        (d)   upon
the occurrence and during the continuance of any Event of Default, to file any claims or take any action or institute any proceedings that Collateral Agent may deem
necessary or desirable for the collection of any of the Collateral or otherwise to enforce the rights of Collateral Agent with respect to any of the Collateral; 

        (e)   to
prepare and file any UCC financing statements against such Grantor as debtor; 

        (f)    to
prepare, sign, and file for recordation in any intellectual property registry, appropriate evidence of the lien and security interest granted herein in the
Intellectual Property in the name of such Grantor as debtor; 

        (g)   to
take or cause to be taken all actions necessary to perform or comply or cause performance or compliance with the terms of this Agreement, including, without
limitation, access to pay or discharge taxes or Liens (other than Permitted Liens) levied or placed upon or threatened against the Collateral, the legality or validity thereof and the amounts
necessary to discharge the same to be determined by Collateral Agent in its sole discretion, any such payments made by Collateral Agent to become obligations of such Grantor to Collateral Agent, due
and payable immediately without demand; and 

        (h)   upon
the occurrence and during the continuance of an Event of Default, generally to sell, transfer, pledge, make any agreement with respect to or otherwise deal with any
of the Collateral as fully and completely as though Collateral Agent were the absolute owner thereof for all purposes, and to do, at Collateral Agent's option and such Grantor's expense, at any time
or from time to time, all acts and things that Collateral Agent deems reasonably necessary to protect, preserve or realize upon the Collateral and Collateral Agent's security interest therein in order
to effect the intent of this Agreement, all as fully and effectively as such Grantor might do. 

        6.2    No Duty on the Part of Collateral Agent or Secured Parties.    The powers conferred on Collateral Agent
hereunder are solely to protect the interests of the Secured Parties in the Collateral and shall not impose any duty upon Collateral Agent or any Secured Party to exercise any such powers. Collateral
Agent and the Secured Parties shall be accountable only for amounts that they actually receive as a result of the exercise of such powers, and neither they nor any of their officers, directors,
employees or agents shall be responsible to any Grantor for any act or failure to act hereunder, except
for their own gross negligence or willful misconduct as determined by a final, nonappealable judgment of a court of competent jurisdiction. 

22

   SECTION 7. REMEDIES.  

        7.1    Generally.    

        (a)   If
any Event of Default shall have occurred and be continuing, Collateral Agent may exercise in respect of the Collateral, in addition to all other rights and remedies
provided for herein or otherwise available to it at law or in equity, all the rights and remedies of Collateral Agent on default under the UCC (whether or not the UCC applies to the affected
Collateral) to collect, enforce or satisfy any Secured Obligations then owing, whether by acceleration or otherwise, and also may pursue any of the following separately, successively or
simultaneously: 

        (i)    require
any Grantor to, and each Grantor hereby agrees that it shall at its expense and promptly upon request of Collateral Agent forthwith, assemble all or part of the
Collateral as directed by Collateral Agent and make it available to Collateral Agent at a place to be designated by Collateral Agent that is reasonably convenient to both parties; 

        (ii)   enter
onto the property where any Collateral is located and take possession thereof with or without judicial process; 

        (iii)  prior
to the disposition of the Collateral, store, process, repair or recondition the Collateral or otherwise prepare the Collateral for disposition in any manner to
the extent Collateral Agent deems appropriate; and 

        (iv)  without
notice except as specified below or under the UCC, sell, assign, lease, license (on an exclusive or nonexclusive basis) or otherwise dispose of the Collateral
or any part thereof in one or more parcels at public or private sale, at any of Collateral Agent's offices or elsewhere, for cash, on credit or for future delivery, at such time or times and at such
price or prices and upon such other terms as Collateral Agent may deem commercially reasonable. 

        (b)   Collateral
Agent or any Secured Party may be the purchaser of any or all of the Collateral at any public or private (to the extent to the portion of the Collateral being
privately sold is of a kind that is customarily sold on a recognized market or the subject of widely distributed standard price quotations) sale in accordance with the UCC and Collateral Agent, as
collateral agent for and representative of the Secured Parties, shall be entitled, for the purpose of bidding and making settlement or payment of the purchase price for all or any portion of the
Collateral sold at any such sale made in accordance with the UCC, to use and apply any of the Secured Obligations as a credit on account of the purchase price for any Collateral payable by Collateral
Agent at such sale. Each purchaser at any such sale shall hold the property sold absolutely free from any claim or right on the part of any Grantor, and each Grantor hereby waives (to the extent
permitted by applicable law) all rights of redemption, stay and/or appraisal which it now has or may at any time in the future have under any rule of law or statute now existing or hereafter enacted.
Each Grantor agrees that, to the extent notice of sale shall be required by law, at least ten (10) days notice to such Grantor of the time and place of any public sale or the time after which
any private sale is to be made shall constitute reasonable notification. Collateral Agent shall not be obligated to make any sale of Collateral regardless of notice of sale having been given.
Collateral Agent may adjourn any public or private sale from time to time by announcement at the time and place fixed therefor, and such sale may, without further notice, be made at the time and place
to which it was so adjourned. Each Grantor agrees that it would not be commercially unreasonable for Collateral Agent to dispose of the Collateral or any portion thereof by using Internet sites that
provide for the auction of assets of the types included in the Collateral or that have the reasonable capability of doing so, or that match buyers and sellers of assets. Each Grantor hereby waives any
claims against Collateral Agent arising by reason of the fact that the price at which any Collateral may have been sold at such a private sale was less than the price which might have been obtained at
a public sale, even if Collateral Agent accepts the 

23

 

first
offer received and does not offer such Collateral to more than one offeree. If the proceeds of any sale or other disposition of the Collateral are insufficient to pay all the Secured
Obligations, Grantors shall be liable for the deficiency and the fees of any attorneys employed by Collateral Agent to collect such deficiency. Each Grantor further agrees that a breach of any of the
covenants contained in this Section will cause irreparable injury to Collateral Agent, that Collateral Agent has no adequate remedy at law in respect of such breach and, as a consequence, that each
and every covenant contained in this Section shall be specifically enforceable against such Grantor, and such Grantor hereby waives and agrees not to assert any defenses against an action for specific
performance of such covenants except for a defense that no default has occurred giving rise to the Secured Obligations becoming due and payable prior to their stated maturities. Nothing in this
Section shall in any way alter the rights of Collateral Agent hereunder. 

        (c)   Collateral
Agent may sell the Collateral without giving any warranties as to the Collateral. Collateral Agent may specifically disclaim or modify any warranties of title
or the like. This procedure will not be considered to adversely affect the commercial reasonableness of any sale of the Collateral. 

        (d)   Collateral
Agent shall have no obligation to marshal any of the Collateral. 

        7.2    Application of Proceeds.    Except as expressly provided elsewhere in this Agreement, all proceeds received by
Collateral Agent in respect of any sale, any collection from, or other realization upon all or any part of the Collateral shall be applied in full or in part by Collateral Agent against, the Secured
Obligations in the following order of priority: first, to the payment of all costs and expenses of such sale, collection or other realization, including
reasonable compensation to Collateral Agent and its agents and counsel, and all other expenses, liabilities and advances made or incurred by Collateral Agent in connection therewith, and all amounts
for which Collateral Agent is entitled to indemnification hereunder (in its capacity as Collateral Agent and not as a Lender) and all advances made by Collateral Agent hereunder for the account of the
applicable Grantor, and to the payment of all costs and expenses paid or incurred by Collateral Agent in connection with the exercise of any right or remedy hereunder or under the Credit Agreement,
all in accordance with the terms hereof or thereof; second, to the payment of all costs, expenses, indemnification claims and other amounts owing to
Administrative Agent under the Credit Documents; third, to the extent of any excess of such proceeds, to the payment of all other Secured Obligations
for the ratable benefit of the Lenders and the Lender Counterparties; and fourth, to the extent of any excess of such proceeds, to the payment to or
upon the order of such Grantor or to whosoever may be lawfully entitled to receive the same or as a court of competent jurisdiction may direct. 

        7.3    Sales on Credit.    If Collateral Agent sells any of the Collateral upon credit, Grantors will be credited only
with payments actually made by purchaser and received by Collateral Agent and applied to indebtedness of the purchaser. In the event the purchaser fails to pay for the Collateral, Collateral Agent may
resell the Collateral and Grantor shall be credited with proceeds of the sale. 

        7.4    Deposit Accounts.    

        If
any Event of Default shall have occurred and be continuing, Collateral Agent may apply the balance from any Deposit Account or instruct the bank at which any Deposit Account is
maintained to pay the balance of any Deposit Account to or for the benefit of Collateral Agent. 

        7.5    Investment Related Property.    

        Each
Grantor recognizes that, by reason of certain prohibitions contained in the Securities Act and applicable state securities laws, Collateral Agent may be compelled, with respect to
any sale of all or any part of the Investment Related Property conducted without prior registration or qualification of such Investment Related Property under the Securities Act and/or such state
securities laws, to limit purchasers to those who will agree, among other things, to acquire the Investment Related Property for 

24

 

their
own account, for investment and not with a view to the distribution or resale thereof. Each Grantor acknowledges that any such private sale may be at prices and on terms less favorable than
those obtainable through a public sale without such restrictions (including a public offering made pursuant to a registration statement under the Securities Act) and, notwithstanding such
circumstances, each Grantor agrees that any such private sale shall be deemed to have been made in a commercially reasonable manner and that Collateral Agent shall have no obligation to engage in
public sales and no obligation to delay the sale of any Investment Related Property for the period of time necessary to permit the issuer thereof to register it for a form of public sale requiring
registration under the Securities Act or under applicable state securities laws, even if such issuer would, or should, agree to so register it. If Collateral Agent determines to exercise its right to
sell any or all of the Investment Related Property, upon written request, each Grantor shall and shall cause each issuer of any Pledged Stock to be sold hereunder, each partnership and each limited
liability company from time to time to furnish to Collateral Agent all such information as Collateral Agent may request in order to determine the number and nature of interest, shares or other
instruments included in the Investment Related Property which may be sold by Collateral Agent in exempt transactions under the Securities Act and the rules and regulations of the Securities and
Exchange Commission thereunder, as the same are from time to time in effect. 

        7.6    Intellectual Property.    

        (a)   Anything
contained herein to the contrary notwithstanding, upon the occurrence and during the continuation of an Event of Default: 

        (i)    Collateral
Agent shall have the right (but not the obligation) to bring suit or otherwise commence any action or proceeding in the name of any Grantor, Collateral Agent
or otherwise, in Collateral Agent's sole discretion, to enforce any of such Grantor's rights in and to any Intellectual Property, in which event such Grantor shall, at the request of Collateral Agent,
do any and all lawful acts and execute any and all documents required by Collateral Agent in aid of such enforcement and such Grantor shall promptly, upon demand, reimburse and indemnify Collateral
Agent as provided in Section 10 hereof in connection with the exercise of its rights under this Section, and, to the extent that Collateral Agent
shall elect not to bring suit to enforce any Intellectual Property as provided in this Section, each Grantor agrees to use all reasonable measures, whether by action, suit, proceeding or otherwise, to
prevent the infringement or other violation of any of such Grantor's rights in the Intellectual Property by others and for that purpose agrees to diligently maintain any such action, suit or
proceeding against any Person so infringing as shall be necessary to prevent such infringement or violation; 

        (ii)   upon
written demand from Collateral Agent, each Grantor shall grant, assign, convey or otherwise transfer to Collateral Agent an absolute assignment of all of such
Grantor's right, title and interest in and to the Intellectual Property and shall execute and deliver to Collateral Agent such documents as are necessary or appropriate to carry out the intent and
purposes of this Agreement; 

        (iii)  each
Grantor agrees that such an assignment and/or recording shall be applied to reduce the Secured Obligations outstanding only to the extent that Collateral Agent
(or any Secured Party) receives cash proceeds in respect of the sale of, or other realization upon, the Intellectual Property; 

        (iv)  Collateral
Agent shall have the right to notify, or require each Grantor to notify, any obligors with respect to amounts due or to become due to such Grantor in respect
of the Intellectual Property, of the existence of the security interest created herein, to direct such obligors to make payment of all such amounts directly to Collateral Agent, and, upon such
notification and at the expense of such Grantor, to enforce collection of any such amounts 

25

 

and
to adjust, settle or compromise the amount or payment thereof, in the same manner and to the same extent as such Grantor might have done; 

        (v)   all
amounts and proceeds (including checks and other instruments) received by such Grantor in respect of amounts due to such Grantor in respect of the Collateral or any
portion thereof shall be received in trust for the benefit of Collateral Agent hereunder, shall be segregated from other funds of such Grantor and shall be forthwith paid over or delivered to
Collateral Agent in the same form as so received (with any necessary endorsement) to be held as cash Collateral and applied as provided by  Section 7.7 hereof; and 

        (vi)  such
Grantor shall not adjust, settle or compromise the amount or payment of any such amount or release wholly or partly any obligor with respect thereto or allow any
credit or discount thereon. 

        (b)   If
(i) an Event of Default shall have occurred and, by reason of cure, waiver, modification, amendment or otherwise, no longer be continuing, (ii) no other
Event of Default shall have occurred and be continuing, (iii) an assignment or other transfer to Collateral Agent of any rights, title and interests in and to the Intellectual Property shall
have been previously made and shall have become absolute and effective, and (iv) the Secured Obligations shall not have become immediately due and payable, upon the written request of any
Grantor, Collateral Agent shall promptly execute and deliver to such Grantor, at such Grantor's sole cost and expense, such assignments or other transfer as may be necessary to reassign to such
Grantor any such rights, title and interests as may have been assigned to Collateral Agent as aforesaid, subject to any disposition thereof that may have been made by Collateral Agent;  provided, after
giving effect to such reassignment, Collateral Agent's security interest granted pursuant hereto, as well as all other rights and
remedies of Collateral Agent granted hereunder, shall
continue to be in full force and effect; and provided further, the rights, title and interests so reassigned shall be free and clear of any other Liens
granted by or on behalf of Collateral Agent and the Secured Parties. 

        (c)   Solely
for the purpose of enabling Collateral Agent to exercise rights and remedies under this Section 7 and at
such time as Collateral Agent shall be lawfully entitled to exercise such rights and remedies, each Grantor hereby grants to Collateral Agent, to the extent it has the right to do so, an irrevocable,
nonexclusive license (exercisable without payment of royalty or other compensation to such Grantor), subject, in the case of Trademarks, to sufficient rights to quality control and inspection in favor
of such Grantor to avoid the risk of invalidation of said Trademarks, to use, operate under, license, or sublicense any Intellectual Property now owned or hereafter acquired by such Grantor, and
wherever the same may be located. 

        7.7    Cash Proceeds.    In addition to the rights of Collateral Agent specified in  Section 4.3 with respect to payments of
Receivables, upon the occurrence and during the continuance of an Event of Default, all proceeds of any
Collateral received by any Grantor consisting of cash, checks and other non-cash items (collectively, "Cash Proceeds") shall be held by such
Grantor in trust for Collateral Agent, segregated from other funds of such Grantor, and shall, forthwith upon receipt by such Grantor, unless otherwise provided pursuant to  Section 4.4(a)(ii), be
turned over to Collateral Agent in the exact form received by such Grantor (duly indorsed by such Grantor to Collateral
Agent, if required) and held by Collateral Agent. Any Cash Proceeds received by Collateral Agent (whether from a Grantor or otherwise): (a) if no Event of Default shall have occurred and be
continuing, shall be paid over to Company unless otherwise provided in the Credit Agreement, and (b) if an Event of Default shall have occurred and be continuing, may, in the sole discretion of
Collateral Agent, (i) be held by Collateral Agent for the ratable benefit of the Secured Parties, as collateral security for the Secured Obligations (whether matured or unmatured) and/or
(ii) then or at any time thereafter may be applied by Collateral Agent against the Secured Obligations then due and owing. 

26

 

SECTION 8. COLLATERAL AGENT.  

        Collateral Agent has been appointed to act as Collateral Agent hereunder by Lenders and, by their acceptance of the benefits hereof, the other Secured Parties.
Collateral Agent shall be obligated, and shall have the right hereunder, to make demands, to give notices, to exercise or refrain from exercising any rights, and to take or refrain from taking any
action (including, without limitation, the release or substitution of Collateral), solely in accordance with this Agreement and the Credit Agreement. In furtherance of the foregoing provisions of this
Section, each Secured Party, by its acceptance of the benefits hereof, agrees that it shall have no right individually to realize upon any of the Collateral hereunder, it being understood and agreed
by such Secured Party that all rights and remedies hereunder may be exercised solely by Collateral Agent for the benefit of Secured Parties in accordance with the terms of this Section. 

SECTION 9. CONTINUING SECURITY INTEREST; TRANSFER OF LOANS.  

        This Agreement shall create a continuing security interest in the Collateral and shall remain in full force and effect until the payment in full of all Secured
Obligations, the cancellation or termination of the Commitments and the cancellation or expiration of all outstanding Letters of Credit, be binding upon each Grantor, its successors and assigns, and
inure, together with the rights and remedies of Collateral Agent hereunder, to the benefit of Collateral Agent and its successors, transferees and assigns. Without limiting the generality of the
foregoing, but subject to the terms of the Credit Agreement, any Lender may assign or otherwise transfer any Loans held by it to any other Person, and such other Person shall thereupon become vested
with all the benefits in respect thereof granted to Lenders herein or otherwise. Upon the payment in full of all Secured Obligations, the termination of the Commitments and the cancellation,
expiration or collateralization in a manner reasonably satisfactory to Collateral Agent of all outstanding Letters of Credit, the security interest granted hereby shall terminate hereunder and of
record and all rights to the Collateral shall revert to Grantors. Upon any such termination Collateral Agent shall, at Grantors' expense, execute and deliver to Grantors such documents as Grantors
shall reasonably request to evidence such termination. 

SECTION 10. STANDARD OF CARE; COLLATERAL AGENT MAY PERFORM.  

        The powers conferred on Collateral Agent hereunder are solely to protect its interest in the Collateral and shall not impose any duty upon it to exercise any such
powers. Except for the exercise of reasonable care in the custody of any Collateral in its possession and the accounting for moneys actually received by it hereunder, Collateral Agent shall have no
duty as to any Collateral or as to the taking of any necessary steps to preserve rights against prior parties or any other rights pertaining to any Collateral. Collateral Agent shall be deemed to have
exercised reasonable care in the custody and preservation of Collateral in its possession if such Collateral is accorded treatment substantially equal to that which Collateral Agent accords its own
property. Neither Collateral Agent nor any of its directors, officers, employees or agents shall be liable for failure to demand, collect or realize upon all or any part of the Collateral or for any
delay in doing so or shall be under any obligation to sell or otherwise dispose of any Collateral upon the request of any Grantor or otherwise. If any Grantor fails to perform any agreement contained
herein, Collateral Agent may itself perform, or cause performance of, such agreement, and the expenses of Collateral Agent incurred in connection therewith shall be payable by each Grantor under
Section 10.2 of the Credit Agreement. 

SECTION 11. MISCELLANEOUS.  

        Any notice required or permitted to be given under this Agreement shall be given in accordance with Section 10.1 of the Credit Agreement. No failure or
delay on the part of Collateral Agent in the exercise of any power, right or privilege hereunder or under any other Credit Document shall impair such power, right or privilege or be construed to be a
waiver of any default or acquiescence therein, 

27

 

nor
shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other power, right or privilege. All rights and remedies existing
under this Agreement and the other Credit Documents are cumulative to, and not exclusive of, any rights or remedies otherwise available. In case any provision in or obligation under this Agreement
shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other
jurisdiction, shall not in any way be affected or impaired thereby. All covenants hereunder shall be given independent effect so that if a particular action or condition is not permitted by any of
such covenants, the fact that it would be permitted by an exception to, or would otherwise be within the limitations of, another covenant shall not avoid the occurrence of a Default or an Event of
Default if such action is taken or condition exists. This Agreement shall be binding upon and inure to the benefit of Collateral Agent and Grantors and their respective successors and assigns. No
Grantor shall, without the prior written consent of Collateral Agent given in accordance with the Credit Agreement, assign any right, duty or obligation hereunder. This Agreement and the other Credit
Documents embody the entire agreement and understanding between Grantors and Collateral Agent and supersede all prior agreements and understandings between such parties relating to the subject matter
hereof and thereof. Accordingly, the Credit Documents may not be contradicted by evidence of prior, contemporaneous or subsequent oral agreements of the parties. There are no unwritten oral agreements
between the parties. This Agreement may be executed in one or more counterparts and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed
an original, but all such counterparts together shall constitute but one and the same instrument; signature pages may be detached from multiple separate counterparts and attached to a single
counterpart so that all signature pages are physically attached to the same document. 

        THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF
THE STATE OF NEW YORK.

[Remainder of page intentionally left blank] 

28

        IN WITNESS WHEREOF, each Grantor and Collateral Agent have caused this Agreement to be duly executed and delivered by their respective
officers thereunto duly authorized as of the date first written above. 

	 	 	MEDICAL DEVICE MANUFACTURING, INC.,

a Colorado corporation
	

 	
 	

By:	

/s/  STEWART A. FISHER      

	 	 	Name:	Stewart A. Fisher
	 	 	Title:	Chief Financial Officer, Vice President, Treasurer & Secretary
	

 	
 	
UTI CORPORATION,
 a Maryland corporation
	

 	
 	

By:	

/s/  STEWART A. FISHER      

	 	 	Name:	Stewart A. Fisher
	 	 	Title:	Chief Financial Officer, Executive Vice President, Treasurer & Secretary

	 	 	AMERICAN TECHNICAL MOLDING, INC.,
 a California corporation
 BRIMFIELD ACQUISITION CORP.,
 a Delaware corporation
 BRIMFIELD PRECISION, LLC,
 a Delaware limited liability company
 CYCAM, INC.,
 a Pennsylvania corporation
 ELX, INC.,

a Pennsylvania corporation
 G&D, INC.,
 a Colorado corporation
 HAYDEN PRECISION INDUSTRIES, LLC,
 a Delaware
limited liability company
 KELCO ACQUISITION, LLC,

a Delaware limited liability company
 MEDSOURCE TECHNOLOGIES, INC.,
 a Delaware corporation
 MEDSOURCE TECHNOLOGIES, LLC,
 a Delaware limited liability company
 MEDSOURCE TECHNOLOGIES NEWTON, INC.,
 a Delaware corporation
 MEDSOURCE TECHNOLOGIES PITTSBURGH, INC.,

a Delaware corporation
 MEDSOURCE TRENTON, INC.,
 a Delaware corporation
 MICRO-GUIDE, INC.,
 a California
corporation
 THE MICROSPRING COMPANY, LLC,
 a Delaware limited liability company
 NATIONAL WIRE & STAMPING, INC.,
 a Colorado
corporation
 NOBLE-MET, LTD.,

a Virginia corporation
 PORTLYN, LLC,
 a Delaware limited liability company
 SPECTRUM MANUFACTURING, INC.,
 a
Nevada corporation
 TENAX, LLC,
 a Delaware limited liability company
 TEXCEL, INC.,
 a Massachusetts corporation
 THERMAT ACQUISITION CORP.,
 a Delaware corporation
	

 	
 	

By:	

/s/  STEWART A. FISHER      

	 	 	Name:	Stewart A. Fisher
	 	 	Title:	Chief Financial Officer, Vice President, Treasurer & Secretary

	 	 	UTI CORPORATION,
 a Pennsylvania corporation
 UTI HOLDING COMPANY,
 a Delaware corporation
 VENUSA, LTD.,

a New York corporation
	

 	
 	

By:	

/s/  STEWART A. FISHER      

	 	 	Name:	Stewart A. Fisher
	 	 	Title:	Chief Financial Officer, Vice President, Treasurer & Secretary

	 	 	CREDIT SUISSE FIRST BOSTON,

acting through its Cayman Islands Branch,
 as Collateral Agent
	

 	
 	

By:	

/s/  JAMES P. MORAN      

	 	 	Name:	James P. Moran
	 	 	Title:	Director
	

 	
 	

By:	

/s/  DENISE L. ALVAREZ      

	 	 	Name:	Denise L. Alvarez
	 	 	Title:	Associate

 
 

Schedule 1
  TO PLEDGE AND SECURITY AGREEMENT    
    

 
 

GENERAL INFORMATION    
    

	(A)
	Full
Legal Name, Type of Organization, Jurisdiction of Organization, Chief Executive Office and Organizational Identification Number of each Grantor: 

	Name of Grantor
 
	 	Type of Organization (e.g. corporation, limited liability company, limited partnership)
	 	Jurisdiction of

Organization/

Formation
	 	Chief Executive Office
	 	Organizational Identification Number

	UTI Corporation	 	Corporation	 	Maryland	 	200 West Seventh Ave.

Collegeville, PA 19426	 	D06082655
	

UTI Corporation	
 	

Corporation	
 	

Pennsylvania	
 	

200 West Seventh Ave.

Collegeville, PA 19426	
 	

366567
	

Medical Device Manufacturing, Inc.	
 	

Corporation	
 	

Colorado	
 	

200 West Seventh Ave.

Collegeville, PA 19426	
 	

20001103370
	

G&D, Inc. d/b/a Star Guide Corporation	
 	

Corporation	
 	

Colorado	
 	

5000 Independence Street

Arvada, Colorado 80002	
 	

19871309595
	

Noble-Met, Ltd.	
 	

Corporation	
 	

Virginia	
 	

200 S. Yorkshire Street

Salem, Virginia 24153	
 	

0330798
	

Spectrum Manufacturing, Inc.	
 	

Corporation	
 	

Nevada	
 	

140 E. Hintz Road

Wheeling, IL 60090	
 	

C6586-1978
	

American Technical Molding, Inc.	
 	

Corporation	
 	

California	
 	

200 West Seventh Ave

Collegeville, PA 19426	
 	

C1443483
	

UTI Holding Company	
 	

Corporation	
 	

Delaware	
 	

2052 West 11th Street

Upland, CA 91786	
 	

3364988

Schedule
1 

	Name of Grantor
 
	 	Type of Organization (e.g. corporation, limited liability company, limited partnership)
	 	Jurisdiction of

Organization/

Formation
	 	Chief Executive Office
	 	Organizational Identification Number

	Micro-Guide, Inc. f/k/a C. and H. Gauge Co., Inc.	 	Corporation	 	California	 	20600 South Street

Tehachapi, CA 93561	 	C0282165
	

Venusa, Ltd.	
 	

Corporation	
 	

New York	
 	

31-C Butterfield Trail

El Paso, Texas 79906	
 	

618895
	

Pine Merger Corporation(1)	
 	

Corporation	
 	

Delaware	
 	

110 Cheshire Lane

Suite 100

Minneapolis, MN 55305	
 	

3789906
	

MedSource Technologies, Inc.	
 	

Corporation	
 	

Delaware	
 	

110 Cheshire Lane

Suite 100

Minneapolis, MN 55305	
 	

2883950
	

MedSource Technologies, LLC	
 	

Limited Liability Company	
 	

Delaware	
 	

110 Cheshire Lane

Suite 100

Minneapolis, MN 55305	
 	

3013277
	

Brimfield Acquisition Corp.	
 	

Corporation	
 	

Delaware	
 	

110 Cheshire Lane

Suite 100

Minneapolis, MN 55305	
 	

2977992
	

Brimfield Precision, LLC	
 	

Limited Liability Company	
 	

Delaware	
 	

110 Cheshire Lane

Suite 100

Minneapolis, MN 55305	
 	

3011487
	

Kelco Acquisition, LLC	
 	

Limited Liability Company	
 	

Delaware	
 	

110 Cheshire Lane

Suite 100

Minneapolis, MN 55305	
 	

2985242

	(1)
	Anticipated
to be merged with MedSource Technologies, Inc. on June 30, 2004, with MedSource Technologies, Inc. surviving the merger. 

Schedule
1 

	Name of Grantor
 
	 	Type of Organization (e.g. corporation, limited liability company, limited partnership)
	 	Jurisdiction of

Organization/

Formation
	 	Chief Executive Office
	 	Organizational Identification Number

	Hayden Precision Industries, LLC	 	Limited Liability Company	 	Delaware	 	110 Cheshire Lane

Suite 100

Minneapolis, MN 55305	 	2993127
	

National Wire & Stamping, Inc.	
 	

Corporation	
 	

Colorado	
 	

110 Cheshire Lane

Suite 100

Minneapolis, MN 55305	
 	

19871144038
	

Portlyn, LLC	
 	

Limited Liability Company	
 	

Delaware	
 	

110 Cheshire Lane

Suite 100

Minneapolis, MN 55305	
 	

2997494
	

Texcel, Inc.	
 	

Corporation	
 	

Massachusetts	
 	

110 Cheshire Lane

Suite 100

Minneapolis, MN 55305	
 	

042973748
	

The Microspring Company, LLC	
 	

Limited Liability Company	
 	

Delaware	
 	

110 Cheshire Lane

Suite 100

Minneapolis, MN 55305	
 	

3018204
	

Tenax, LLC	
 	

Limited Liability Company	
 	

Delaware	
 	

110 Cheshire Lane

Suite 100

Minneapolis, MN 55305	
 	

3154069
	

Thermat Acquisition Corp.	
 	

Corporation	
 	

Delaware	
 	

110 Cheshire Lane

Suite 100

Minneapolis, MN 55305	
 	

3220037
	

MedSource Technologies Newton, Inc.	
 	

Corporation	
 	

Delaware	
 	

110 Cheshire Lane

Suite 100

Minneapolis, MN 55305	
 	

3314037
	

MedSource Technologies Pittsburgh, Inc.	
 	

Corporation	
 	

Delaware	
 	

110 Cheshire Lane

Suite 100

Minneapolis, MN 55305	
 	

3181236

Schedule
1 

	Name of Grantor
 
	 	Type of Organization (e.g. corporation, limited liability company, limited partnership)
	 	Jurisdiction of

Organization/

Formation
	 	Chief Executive Office
	 	Organizational Identification Number

	MedSource Trenton, Inc.	 	Corporation	 	Delaware	 	110 Cheshire Lane

Suite 100

Minneapolis, MN 55305	 	3465880
	

Cycam, Inc.	
 	

Corporation	
 	

Pennsylvania	
 	

110 Cheshire Lane

Suite 100

Minneapolis, MN 55305	
 	

1017213
	

ELX, Inc.	
 	

Corporation	
 	

Pennsylvania	
 	

110 Cheshire Lane

Suite 100

Minneapolis, MN 55305	
 	

2497469

	(B)
	Other
Names (including any Trade-Name or Fictitious Business Name) under which each Grantor has conducted business for the Five Years Preceding the Closing Date: 

	Full Legal Name
 
	 	Trade Name or Fictitious Business Name

	Medical Device Manufacturing, Inc.	 	d/b/a Rivo Technologies
	

G&D, Inc.	
 	

d/b/a Star Guide Corporation
	

Micro-Guide, Inc.	
 	

f/k/a C&H Gauge Co., Inc.

Schedule
1 

	(C)
	Changes
in Name, Jurisdiction of Organization, Chief Executive Office or Sole Place of Business and Corporate Structure within the Five Years Preceding the Closing Date: 

	Name of Grantor
 
	 	Date of Change
	 	Description of Change

	Medical Engineering Resources, Ltd.	 	12/31/03	 	Merged with and into G & D, Inc. d/b/a Star Guide Corporation
	

Micro-Guide, Inc.	
 	

12/31/03	
 	

Merged with and into C. and H. Gauge Co., Inc.
	

C. and H. Gauge Co., Inc.	
 	

12/31/03	
 	

Changed name to Micro-Guide, Inc.
	

MedSource Technologies Newton, Inc.	
 	

12/29/00	
 	

Changed name from ACT Acquisition Corp. following merger with ACT Medical, Inc.
	

Pine Merger Corporation	
 	

Anticipated 6/30/04	
 	

Merging with and into MedSource Technologies, Inc.
	

National Wire & Stamping, Inc.	
 	

 	
 	

Prior Address: 55 Deer Park Dr., East Longmeadow, MA 01118
	

ELX, Inc.	
 	

 	
 	

Prior Address: 149 Johnson Road, PO Box 155, Houston, PA 15342
	

Cycam, Inc.	
 	

 	
 	

Prior Address: 149 Johnson Road, PO Box 155, Houston, PA 15342

	(D)
	Financing
Statements: 

	Name of Grantor
 
	 	Filing Jurisdiction(s)

	UTI Corporation, Maryland corporation	 	Maryland—State Department of Assessments and Taxation
	

UTI Corporation, a Pennsylvania corporation	
 	

Pennsylvania—Department of State
	

Medical Device Manufacturing, Inc.	
 	

Colorado—Secretary of State
	

G&D, Inc. d/b/a Star Guide Corporation	
 	

Colorado—Secretary of State
	

Noble-Met, Ltd.	
 	

Virginia—State Corporation Commission
	

Spectrum Manufacturing, Inc.	
 	

Nevada—Secretary of State
	

American Technical Molding, Inc.	
 	

California—Secretary of State
	

UTI Holding Company	
 	

Delaware—Secretary of State
	

Micro-Guide, Inc. f/k/a C. and H. Gauge Co., Inc.	
 	

California—Secretary of State
	

Venusa, Ltd.	
 	

New York—Department of State
	

Pine Merger Corporation	
 	

Delaware—Secretary of State

Schedule
1 

	Name of Grantor
 
	 	Filing Jurisdiction(s)

	MedSource Technologies, Inc.	 	Delaware—Secretary of State
	

MedSource Technologies, LLC	
 	

Delaware—Secretary of State
	

Brimfield Acquisition Corp.	
 	

Delaware—Secretary of State
	

Brimfield Precision, LLC	
 	

Delaware—Secretary of State
	

Kelco Acquisition, LLC	
 	

Delaware—Secretary of State
	

Hayden Precision Industries, LLC	
 	

Delaware—Secretary of State
	

National Wire & Stamping, Inc.	
 	

Colorado—Secretary of State
	

Portlyn, LLC	
 	

Delaware—Secretary of State
	

Texcel, Inc.	
 	

Massachusetts—Secretary of the Commonwealth
	

The Microspring Company, LLC	
 	

Delaware—Secretary of State
	

Tenax, LLC	
 	

Delaware—Secretary of State
	

Thermat Acquisition Corp.	
 	

Delaware—Secretary of State
	

MedSource Technologies Newton, Inc.	
 	

Delaware—Secretary of State
	

MedSource Technologies Pittsburgh, Inc.	
 	

Delaware—Secretary of State
	

MedSource Trenton, Inc.	
 	

Delaware—Secretary of State
	

Cycam, Inc.	
 	

Pennsylvania—Department of State
	

ELX, Inc.	
 	

Pennsylvania—Department of State

Schedule
1 

 
 

Schedule 2
  TO PLEDGE AND SECURITY AGREEMENT    
    

	Name of Grantor
 
	 	Location of Equipment and Inventory

	G&D, Inc. d/b/a Star Guide Corporation	 	5000 Independence Street

Arvada, Colorado 80002
	

Noble-Met, Ltd.	
 	

200 & 221 S. Yorkshire Street

Salem, Virginia 24153
	

UTI Corporation (PA)	
 	

200 W. 7th Avenue

Collegeville, PA 19426
	

UTI Corporation (PA)	
 	

4315 New Brunswick Avenue

South Plainfield, NJ 07080
	

UTI Corporation (PA)	
 	

169 Callender Road

Watertown, CT 06795
	

UTI Corporation (PA)	
 	

3rd and Penn Streets(2)

Pottstown, PA 19464
	

Spectrum Manufacturing, Inc.	
 	

140 E. Hintz Road

Wheeling, IL 60090
	

Spectrum Manufacturing, Inc.	
 	

690 & 723 Chaddick Drive Wheeling, IL 60090
	

American Technical Molding, Inc.	
 	

2052 West 11th Street

Upland, CA 91786
	

Micro-Guide, Inc.	
 	

20600 South Street and 20601 Santa Lucia Street

Tehachapi, CA 93561
	

Venusa, Ltd.	
 	

31-C Butterfield Trail

El Paso, TX 79906
	

MedSource Technologies, LLC	
 	

110 Cheshire Lane, Suite 100

Minneapolis, MN 55305
	

Brimfield Precision, LLC	
 	

68 Mill Lane Road

Brimfield, MA 01010
	

Kelco Acquisition, LLC	
 	

6420 Zane Avenue North

Brooklyn Park, MN 55429
	

Hayden Precision Industries, LLC	
 	

3902 California Road

Orchard Park, NY 14127
	

National Wire & Stamping, Inc.	
 	

2801 South Vallejo Street

Englewood, CO 80110
	

Portlyn, LLC	
 	

45 Lexington Drive

Laconia, NH 03246
	

	(2)
	This
location is warehouse space. UTI does not lease space, but is charged as inventory is

moved. 

   

Schedule 2 

	 
	 	 

	The Microspring Company, LLC	 	77 Accord Park Drive, Suite A

Norwell, MA 02061
	

Thermat Acquisition Corp.	
 	

380 Sciota Street

Corry, PA 16407
	

MedSource Technologies Newton, Inc.	
 	

150 California Street

Newton, MA 02458
	

MedSource Trenton, Inc.	
 	

13024 North Main Street and 129 Bond Street

Trenton, GA 30752
	

Cycam, Inc.	
 	

149 Johnson Road

Houston, PA 15342
	

ELX, Inc.	
 	

149 Johnson Road

Houston, PA 15342
	

The Microspring Company, LLC	
 	

51 Parmenter Road

Hudson, MA 01749
	

The Microspring Company, LLC	
 	

58 McDonald Street

Dedham, MA 02026
	

The Microspring Company, LLC	
 	

1969 Clearview Road

Souderton, PA 18964
	

The Microspring Company, LLC	
 	

15 Commerce Way

Norton, MA 02766
	

MedSource Technologies Newton, Inc.	
 	

Talamante y Josefa Ortiz de Dominguez

Navojoa, Sonora, Mexico, 85800
	

MedSource Technologies Newton, Inc.	
 	

1456 North Calle Plata

Nogales, AZ 85621
	

Cycam, Inc.	
 	

4915 21st Street

Racine, WI 53406
	

Cycam, Inc.	
 	

21316 Bridge Street

Southfield, MI 48034
	

Cycam, Inc.	
 	

24 Aldrin Road

Plymouth, MA 02360
	

Cycam, Inc.	
 	

1 Grant Road

Ridgway, PA 15853
	

Cycam, Inc.	
 	

7196 North State Road 13

North Webster, IN 46555
	

Cycam, Inc.	
 	

R.D. #9, Box 610, Old Route 66

Greensburg, PA 15601
	

Cycam, Inc.	
 	

2713 Foundation Drive

South Bend, IN 46628
	

Cycam, Inc.	
 	

East 64 Midland Avenue

Paramus, NJ 07852

   

Schedule 2 

	 
	 	 

	Cycam, Inc.	 	1220 Industrial Drive

Erie, PA 16505
	

Cycam, Inc.	
 	

215 Race Street

Meadville, PA 16335
	

Cycam, Inc.	
 	

350 Hochberg Road

Monroeville, PA 15146
	

Cycam, Inc.	
 	

2100 Roosevelt Avenue

Springfield, MA 15146
	

Cycam, Inc.	
 	

9 Apollo Drive

Whippany, NJ 07981
	

Cycam, Inc.	
 	

15 Allegheny Square

Glassport, PA 15045
	

Cycam, Inc.	
 	

Old Route 20

Westmoreland, PA 15696
	

Cycam, Inc.	
 	

2100 North Detroit Street

Warsaw, IN 46580
	

Thermat Acquisition Corp.	
 	

1 Plastics Road

Corry, PA 16407
	

Thermat Acquisition Corp.	
 	

1370 Lavelle Drive

Xenia, OH 45385
	

Thermat Acquisition Corp.	
 	

2122 Winners Circle

Dayton, OH 45404
	

Thermat Acquisition Corp.	
 	

30 Industrial Road

Hermitage, PA 16148
	

Thermat Acquisition Corp.	
 	

100 Deposition Drive

Clear Lake, WI 54005
	

Thermat Acquisition Corp.	
 	

54 Eisenhower Lane North

Lombard, IL 60148
	

Thermat Acquisition Corp.	
 	

60 Church Street

Yalesville, CT 06492
	

Thermat Acquisition Corp.	
 	

4976 Franklin Avenue

Fairview, PA 16415
	

Thermat Acquisition Corp.	
 	

3781 Port Union Road

Fairfield, OH 45014
	

Thermat Acquisition Corp.	
 	

3701 Hawkins Street NE

Albuquerque, NM 87109
	

Thermat Acquisition Corp.	
 	

6420 Zane Avenue North

Brooklyn Park, MN 55429
	

Thermat Acquisition Corp.	
 	

115 Island Brook Avenue

Bridgeport, CT 06606

   

Schedule 2 

	 
	 	 

	Thermat Acquisition Corp.	 	425B Pan American Drive

El Paso, TX 79907
	

Thermat Acquisition Corp.	
 	

5600 Second Street NW

Albuquerque, NM 87107
	

Portlyn, LLC	
 	

209 Bowles Road

Agawam, MA 01001
	

Portlyn, LLC	
 	

187 Water Street

Laconia, NH 02346
	

Portlyn, LLC	
 	

400 Canal Street

Lawrence, MA 01840
	

Portlyn, LLC	
 	

15 Commerce Way

Norton, MA 02766
	

Portlyn, LLC	
 	

435 Whitney Street

Northboro, MA 01530
	

Portlyn, LLC	
 	

1049 Tiogue Ave

Coventry, RI 02816
	

Portlyn, LLC	
 	

248 Main Street E

Greenville, PA 18041
	

Portlyn, LLC	
 	

11666 McBean Drive

El Monte, CA 91732
	

Portlyn, LLC	
 	

94 Calvary Street

Waltham, MA 02454
	

Portlyn, LLC	
 	

30958 San Antonio Street

Hayward, CA 94544
	

Portlyn, LLC	
 	

9020 Activity Road, Suite D

San Diego, CA 92126
	

Portlyn, LLC	
 	

3310 Montgomery Drive

Santa Clara, CA 95054
	

Hayden Precision Industries, LLC	
 	

2001 South Kilbourn Avenue

Chicago, IL 60623
	

Hayden Precision Industries, LLC	
 	

248 West Centralia Street

Elkhorn, WI 53121
	

Hayden Precision Industries, LLC	
 	

459 Pulaski Street

Syracuse, NY 14228
	

Hayden Precision Industries, LLC	
 	

525 Vickers Street

Tonawanda, NY 14150
	

Hayden Precision Industries, LLC	
 	

44 Laporte Street

Arcadia, CA 91066
	

Hayden Precision Industries, LLC	
 	

63 Alhambra Road

Warwick, RI 02886

   

Schedule 2 

	 
	 	 

	Hayden Precision Industries, LLC	 	60 Mill Lane Road

Brimfield, MA 01010
	

Hayden Precision Industries, LLC	
 	

1112 Niagara Street

Buffalo, NY 14213
	

Hayden Precision Industries, LLC	
 	

Chessington Indust. Estate

Roebuck Road, Chessington,

Surrey KT9 1LR, England
	

Hayden Precision Industries, LLC	
 	

209 Bowles Road

Agawam, MA 01001
	

Hayden Precision Industries, LLC	
 	

94 Calvary Street

Waltham, MA 02454
	

Hayden Precision Industries, LLC	
 	

2316 West Wisconsin Street

Portage, WI 53910
	

Hayden Precision Industries, LLC	
 	

10811 Withers Cove Park Drive

Charlotte, NC 28278
	

Hayden Precision Industries, LLC	
 	

6 Apollo Drive

Batavia, NY 14020
	

Hayden Precision Industries, LLC	
 	

Roblin Industrial Park, 4000 River Road

Tonawanda, NY 14150
	

Hayden Precision Industries, LLC	
 	

425 Pan American Drive

El Paso, TX 79907
	

Kelco Acquisition, LLC	
 	

Veddestavagen 19

SE-175 62 Jarfalla, Sweden
	

Kelco Acquisition, LLC	
 	

123 South Columbus Avenue

Mount Vernon, NY 10553
	

Kelco Acquisition, LLC	
 	

D-63450, Hanau

Germany
	

Brimfield Precision, LLC	
 	

1081 Bristol Road

Mountainside, NJ 07092
	

Brimfield Precision, LLC	
 	

105 York Street

Kennebunk, ME 04043
	

Brimfield Precision, LLC	
 	

141 Davenport Street

Bridgeport, CT 06607
	

Brimfield Precision, LLC	
 	

45 Baldwin Street

East Longmeadow, MA 01028
	

Brimfield Precision, LLC	
 	

113 Bethany Road

Monson, MA 01057
	

Brimfield Precision, LLC	
 	

60 Brockway Road

Woodstock Valley, CT 06282

   

Schedule 2 

	 
	 	 

	Brimfield Precision, LLC	 	748 River Street

Palmer, MA 01069
	

Brimfield Precision, LLC	
 	

2100 Roosevelt Avenue

Springfield, MA 01102
	

Brimfield Precision, LLC	
 	

40 Earls Way, Suite 2

Franklin, MA 02038
	

Brimfield Precision, LLC	
 	

21316 Bridge Street

Southfield, MI 48034
	

Brimfield Precision, LLC	
 	

65 Woodlawn Avenue

Pawtucket, RI 02860
	

Brimfield Precision, LLC	
 	

Bethany Road, P.O. Box 84

Monson, MA 01057
	

Brimfield Precision, LLC	
 	

241 Crescent Street Rear

Waltham, MA 02453
	

Brimfield Precision, LLC	
 	

19 Fairview Drive

Leicester, MA 01524
	

Brimfield Precision, LLC	
 	

44 Laporte Street

Arcadia, CA 91066
	

Brimfield Precision, LLC	
 	

17 Connecticut Drive South

E. Granby, CT 06026
	

Brimfield Precision, LLC	
 	

122 Cascade Boulevard

Milford, CT 06460
	

National Wire & Stamping, Inc.	
 	

2001 South Kilbourn Avenue

Chicago, IL 60623
	

National Wire & Stamping, Inc.	
 	

2960 South Umatilla Street

Englewood, CO 80110
	

National Wire & Stamping, Inc.	
 	

638 Elkton Drive

Colorado Springs, CO 80907
	

National Wire & Stamping, Inc.	
 	

3100 East 43rd Avenue

Denver, CO 80216
	

National Wire & Stamping, Inc.	
 	

6940 Farmdale Avenue

N. Hollywood, CA 91605
	

National Wire & Stamping, Inc.	
 	

3057 Delta Drive

Colorado Springs, CO 80910
	

National Wire & Stamping, Inc.	
 	

3525 North Cascade Avenue

Colorado Springs, CO 80907
	

National Wire & Stamping, Inc.	
 	

600 West E Street

Lincoln, NE 68522
	

National Wire & Stamping, Inc.	
 	

4575 South Navajo

Englewood, CO 80110

   

Schedule 2 

	 
	 	 

	National Wire & Stamping, Inc.	 	2191 West Amherst

Englewood, CO 80110
	

National Wire & Stamping, Inc.	
 	

12660 Pennsylvania

Denver, CO 80223
	

National Wire & Stamping, Inc.	
 	

4827 Chelsea

Kansas City, MO 64130
	

National Wire & Stamping, Inc.	
 	

18001 Railroad Street

City of Industry, CA 91748
	

National Wire & Stamping, Inc.	
 	

3839 Newport Street

Denver, CO 80217
	

National Wire & Stamping, Inc.	
 	

Building #9, Schenley Industrial Park

Schenley, PA 15682
	

National Wire & Stamping, Inc.	
 	

9 Technologies Drive

Staunton, VA 24401
	

National Wire & Stamping, Inc.	
 	

100 Deposition Drive

Clear Lake, WI 54005
	

National Wire & Stamping, Inc.	
 	

10477 Weld County

Longmont, CO 80501
	

National Wire & Stamping, Inc.	
 	

205 Tuner

Berthoud, CO 80513
	

National Wire & Stamping, Inc.	
 	

14700 West 66th Place

Arvada, CO 80004
	

National Wire & Stamping, Inc.	
 	

3457 Brighton Boulevard

Denver, CO 80216
	

National Wire & Stamping, Inc.	
 	

4343 Platte Avenue

Sedalia, CO 80223

   

Schedule 2 

 
 

Schedule 3
  TO PLEDGE AND SECURITY AGREEMENT    
    

 
 

INVESTMENT RELATED PROPERTY    
    

Pledged
Stock: 

	Grantor
 
	 	Stock Issuer
	 	Class of

Stock
	 	Certificated

(Y/N)
	 	Stock

Certificate

No.
	 	Par

Value
	 	No. of

Pledged

Stock
	 	% of

Outstanding

Stock of the

Stock Issuer

	UTI Corporation (MD)	 	Medical Device Manufacturing, Inc.	 	Common	 	Y	 	2	 	$.01	 	100	 	100
	

Medical Device Manufacturing, Inc.	
 	

G&D, Inc. d/b/a Star Guide Corporation	
 	

Class A Common

Class B Common	
 	

Y

Y	
 	

38

39	
 	

no par

no par	
 	

100,000

9,900,000	
 	

100

	

Medical Device Manufacturing, Inc.	
 	

Noble-Met, Ltd.	
 	

Common	
 	

Y	
 	

38	
 	

no par	
 	

4,113,282	
 	

100
	

Medical Device Manufacturing, Inc.	
 	

Venusa, Ltd.	
 	

Common	
 	

Y	
 	

6	
 	

no par	
 	

70	
 	

100
	

Medical Device Manufacturing, Inc.	
 	

American Technical Molding, Inc.	
 	

Common	
 	

Y	
 	

C-4	
 	

no par	
 	

100	
 	

100
	

Medical Device Manufacturing, Inc.	
 	

UTI Holding Company	
 	

Common	
 	

Y	
 	

C-1	
 	

$.01	
 	

100	
 	

100
	

Medical Device Manufacturing, Inc.	
 	

Micro-Guide, Inc.	
 	

Common	
 	

Y	
 	

65	
 	

no par	
 	

91,388	
 	

100
	

Medical Device Manufacturing, Inc.	
 	

MedSource Technologies, Inc.	
 	

Common	
 	

Y	
 	

1	
 	

$.01	
 	

100	
 	

100
	

Medical Device Manufacturing, Inc.	
 	

UTI Corporation (PA)	
 	

Common	
 	

Y	
 	

A127	
 	

$.01	
 	

13,144	
 	

100

Schedule
3 

	Grantor
 
	 	Stock Issuer
	 	Class of

Stock
	 	Certificated

(Y/N)
	 	Stock

Certificate

No.
	 	Par

Value
	 	No. of

Pledged

Stock
	 	% of

Outstanding

Stock of the

Stock Issuer

	Medical Device Manufacturing, Inc.	 	UTI Corporation (PA)	 	Common	 	Y	 	B143	 	$.01	 	1,547,319	 	100
	

UTI Corporation (PA)	
 	

Spectrum Manufacturing Inc. (Nevada)	
 	

Common	
 	

Y	
 	

11	
 	

no par	
 	

300	
 	

100
	

Medical Device Manufacturing, Inc.	
 	

Venusa de Mexico, S.A. de C.V.	
 	

Series B Foreign Fixed Capital

Series B Foreign Variable Capital	
 	

Y

Y	
 	

1

2	
 	

 	
 	

100

25	
 	

Both represent 65.1%
	

UTI Corporation (PA)	
 	

UTISFM Feinmechanik GmbH (Germany)	
 	

Common	
 	

N	
 	

 	
 	

 	
 	

 	
 	

65
	

Medical Device Manufacturing, Inc.	
 	

Medis S.A. de C.V.	
 	

Series B Fixed Foreign Capital	
 	

Y	
 	

6	
 	

 	
 	

65	
 	

65
	

G&D Inc. d/b/a Star Guide Corporation	
 	

Star Guide, Ltd.	
 	

Common	
 	

Y	
 	

4	
 	

€1	
 	

1	
 	

50
	

MedSource Technologies, LLC	
 	

Brimfield Acquisition Corp.	
 	

Common	
 	

Y	
 	

2	
 	

$.01	
 	

100	
 	

100
	

MedSource Technologies, LLC	
 	

National Wire & Stamping, Inc.	
 	

Common	
 	

Y	
 	

Un-

numbered	
 	

$.8635	
 	

10	
 	

100
	

MedSource Technologies, LLC	
 	

Texcel, Inc.	
 	

Common	
 	

Y	
 	

13	
 	

no par	
 	

10	
 	

100
	

MedSource Technologies, LLC	
 	

Thermat Acquisition Corp.	
 	

Common	
 	

Y	
 	

C-1	
 	

$.01	
 	

200	
 	

100

Schedule 3 

	Grantor
 
	 	Stock Issuer
	 	Class of

Stock
	 	Certificated

(Y/N)
	 	Stock

Certificate

No.
	 	Par

Value
	 	No. of

Pledged

Stock
	 	% of

Outstanding

Stock of the

Stock Issuer

	MedSource Technologies, LLC	 	MedSource Technologies Newton, Inc.	 	Common	 	Y	 	2	 	$.01	 	100	 	100
	

MedSource Technologies, LLC	
 	

MedSource Technologies Pittsburgh, Inc.	
 	

Common	
 	

Y	
 	

C-1	
 	

$.01	
 	

100	
 	

100
	

MedSource Technologies, LLC	
 	

MedSource Trenton, Inc.	
 	

Common	
 	

Y	
 	

C-1	
 	

$.01	
 	

100	
 	

100
	

MedSource Technologies Pittsburgh, Inc.	
 	

Cycam, Inc.	
 	

Common	
 	

Y	
 	

6	
 	

$1.00	
 	

500	
 	

100
	

MedSource Technologies Pittsburgh, Inc.	
 	

ELX, Inc.	
 	

Common	
 	

Y	
 	

3	
 	

$50.00	
 	

60	
 	

100

       

 

Pledged
LLC Interests Not Elected to be Treated as Securities: 

	Grantor
 
	 	Limited Liability Company
	 	Certificated (Y/N)
	 	Certificate No. (if any)
	 	No. of Pledged Units
	 	% of Outstanding LLC Interests of the Limited Liability Company

	MedSource Technologies, Inc.	 	MedSource Technologies, LLC	 	N	 	N/A	 	 	 	100
	

MedSource Technologies, LLC	
 	

Brimfield Precision, LLC	
 	

N	
 	

N/A	
 	

 	
 	

100
	

MedSource Technologies, LLC	
 	

Kelco Acquisition, LLC	
 	

N	
 	

N/A	
 	

 	
 	

100
	

MedSource Technologies, LLC	
 	

Hayden Precision Industries, LLC	
 	

N	
 	

N/A	
 	

 	
 	

100
	

MedSource Technologies, LLC	
 	

Portlyn, LLC	
 	

N	
 	

N/A	
 	

 	
 	

100
	

MedSource Technologies, LLC	
 	

The Microspring Company, LLC	
 	

N	
 	

N/A	
 	

 	
 	

100
	

MedSource Technologies, LLC	
 	

Tenax, LLC	
 	

N	
 	

N/A	
 	

 	
 	

100

Schedule
3 

Pledged
LLC Interests Elected to be Treated as Securities: 

None.

	Grantor
 
	 	Limited Liability Company
	 	Certificated (Y/N)
	 	Certificate No.

(if any)
	 	No. of Pledged

Units
	 	% of Outstanding LLC

Interests of

the Limited Liability

Company

       

 

Pledged
Partnership Interests Not Elected to be Treated as Securities: 

None.

	Grantor
 
	 	Partnership
	 	Type of Partnership Interests (e.g.,

general or limited)
	 	Certificated (Y/N)
	 	Certificate No.

(if any)
	 	% of Outstanding

Partnership

Interests of the

Partnership

       

 

Pledged
Partnership Interests Elected to be Treated as Securities: 

None.

	Grantor
 
	 	Partnership
	 	Type of Partnership Interests (e.g.,

general or limited)
	 	Certificated (Y/N)
	 	Certificate No.

(if any)
	 	% of Outstanding

Partnership

Interests of the

Partnership

Schedule
3 

Pledged
Trust Interests: 

None.

	Grantor
 
	 	Trust
	 	Change of Trust Interests
	 	Certificated (Y/N)
	 	Certificate No.

(if any)
	 	% of Outstanding

Trust Interests of the Trust

       

 

        Warrants,
Options, Shareholder Agreements or Voting Trust Agreements Relating to Pledged Equity Interests: 

        Please
see attached option schedule for UTI, a Maryland corporation and its subsidiaries current through March 31, 2003 attached hereto as Annex
A. 

        Please
see attached option schedule for MedSource Technologies, Inc. and its subsidiaries current through April 9, 2004 attached hereto as Annex
B. 

        Anti-Dilution
Agreement by and among MDMI Holdings, Inc. and the Parties named therein, dated May 31, 2000. 

        Second
Amended and Restated Registration Rights Agreement by and among MDMI Holdings, Inc., KRG Capital Fund, L.P., KRG Capital Fund I (FF), L.P., KRG Capital Fund I (PA), L.P.,
KRG Co-Investment, L.L.C. and the Holders listed therein on Schedule I, dated as of May 31, 2000, as amended by the Amendment of the Amended and Restated Registration Rights
Agreement approved February 23, 2003. 

        Shareholders'
Agreement, by and among Medical Device Manufacturing, Inc., KRG Capital Partners, LLC, Eric Pollock, Helene Pollock, the Helene Pollock Irrevocable Spousal Trust
No. 1, the Helene Pollock Irrevocable Spousal Trust No. 2, George Archambault, Patricia Harrison, Donald Bothner, First Analysis Corporation and its affiliated investment funds,
Infrastructure and Environmental Private Equity Fund III, L.P. and Environmental and Information Technology Private Fund III, CMC Companies and any affiliated investment fund to which it may assign
all or part of its interest in the Company, and such other investors as may from time to time become a party, dated as of July 6, 1999, as amended. 

        Stock
Purchase Agreement by and among UTI Corporation, Medical Device Manufacturing and CISA, Ltd., Giancarlo Gagliardoni and Cesare Gagliardoni, dated February 28, 2003. 

        UTI
Corporation has outstanding currently exercisable warrants to purchase an aggregate of 1,136,364 shares of its Class AB Convertible Preferred Stock at an exercise price of $0.01 per
share. Each share of Class AB Convertible Preferred Stock issuable upon exercise of the warrants is convertible into 1.8 shares of UTI Corporation's common stock. The warrants are held by the holders
of UTI Corporation's Class C Redeemable Preferred Stock and entitle each holder thereof to acquire that number of shares of Class AB Convertible Preferred Stock equal to the number of shares of
Class C Redeemable Preferred Stock held by each such holder. 

Schedule
3 

Pledged
Debt: 

	Grantor
 
	 	Issuer
	 	Original Principal

Amount
	 	Outstanding Principal

Balance
	 	Issue Date
	 	Maturity Date

	Cycam, Inc.	 	Islet Sheet Metal, Inc	 	$50,000	 	 	 	July 24, 2000	 	June 1, 2005

       

 

Securities
Account: 

MedSource
securities accounts listed on the Collateral Questionnaire are in the process of being closed. 

	Grantor
 
	 	Share of Securities Intermediary
	 	Account Number
	 	Account Name

       

 

Commodities
Accounts: 

None.

	Grantor
 
	 	Name of Commodities
	 	Account Number
	 	Account Name

       

 

Deposit
Accounts: 

	Grantor
 
	 	Name of Depositary Bank
	 	Account Number
	 	Account Name

	Medical Device Manufacturing, Inc.	 	Fleet	 	 	 	Concentration Account
	

*UTI Corporation (Maryland)	
 	

PNC Bank	
 	

 	
 	

General Account
	

*Venusa, Ltd.	
 	

Wells Fargo Bank, 6715

Gateway Blvd., West El Paso Texas 79912	
 	

 	
 	

Checking Account
	

MedSource Technologies, LLC	
 	

U.S. Bank, N.A.

601 Second Avenue South

Minneapolis, MN 55402	
 	

 	
 	

Checking Account
	

MedSource Technologies, LLC	
 	

U.S. Bank, N.A.601 Second Avenue South

Minneapolis, MN 55402	
 	

 	
 	

Checking Account (Health Plan)

	*
	In
process of being closed. 

Schedule
3 

 
 

Schedule 4
  TO PLEDGE AND SECURITY AGREEMENT    
    

	Name of Grantor
 
	 	Description of Letters of Credit

	None.	 	 

   

Schedule 4 

 
 

Schedule 5
  TO PLEDGE AND SECURITY AGREEMENT    
    

Patents and Patent Applications owned by each Grantor  

MEDSOURCE TECHNOLOGIES, INC.  

Patents  

None 

MEDSOURCE TECHNOLOGIES, LLC  

Patents  

i.    US Patents 

	Patent No.
 
	 	Title
	 	Issue Date

	6,578,402	 	Trimming Apparatus for a Drawn Part	 	June 17, 2003

BRIMFIELD PRECISION, LLC  

Patents  

None 

KELCO ACQUISITION LLC  

Patents  

None 

HAYDEN ACQUISITION, LLC  

Patents  

None 

NATIONAL WIRE & STAMPING, INC.  

Patents  

None 

  

Schedule 5 

PORTLYN, LLC  

Patents  

i.    US Patents 

	Patent No.
 
	 	Title
	 	Issue Date

	5,766,197	 	Surgical Cutting Instrument with Anti-Torque Jacket	 	June 16, 1998
	

5,571,129	
 	

Surgical Cutting Instrument with Improved Cleaning Capability and Ease of Use	
 	

November 5, 1996

TEXCEL, INC.  

Patents  

None 

THE MICROSPRING COMPANY, LLC  

Patents  

i.    US Patents 

	Patent No.
 
	 	Title
	 	Issue Date

	5,876,783	 	Radiopaque Medical Devices	 	March 2, 1999
	

5,606,979	
 	

Guide Wire	
 	

March 4, 1997
	

6,620,172	
 	

Entraining Biological Calculi	
 	

September 16, 2003

ii    Foreign Applications 

	Application No.
 
	 	Title
	 	Date Filed
	 	Country

	JP507375	 	Medical Receiver Device	 	June 30, 2000	 	Japan
	

00947024.6	
 	

Medical Retriever Device	
 	

June 30, 2000	
 	

Europe
	

2001/01350	
 	

Medical Retriever Device	
 	

June 30, 2000	
 	

India

TENAX, LLC  

Patents  

None 

A.P.X. ACQUISITION CORP. 

Patents  

None 

  

Schedule 5 

THERMAT ACQUISITION CORP.  

Patents  

i.    US Patents 

	Patent No.
 
	 	Title
	 	Issue Date

	5,641,920	 	Power and Binder Systems for use in Power Molding	 	June 24, 1997
	

5,950,063	
 	

Method of Power Injection Molding	
 	

September 7, 1999

ii    Foreign Patents 

	Patent No.
 
	 	Title
	 	Date Filed
	 	Country

	712638	 	Powder and binder systems for use in powder molding	 	February 24, 2000	 	Australia
	

2,230,994	
 	

Powder and binder systems for use in powder molding	
 	

 	
 	

Canada
	

96512740	
 	

 	
 	

 	
 	

Japan
	

98/1,623	
 	

 	
 	

 	
 	

Mexico
	

738589	
 	

Method of powder injection molding	
 	

November 2, 2000	
 	

Australia

MEDSOURCE TECHNOLOGIES, NEWTON INC.  

Patents  

i.    US Patents 

	Patent No.
 
	 	Title
	 	Issue Date

	5,256,158*	 	Device having a radiopaque marker for endoscopic accessories and method of making same	 	October 26, 1993
	

5,256,144	
 	

Low Profile, High Performance Interventional Catheters	
 	

October 26, 1993
	

5,201,756**	
 	

Radically-Expandable Tubular Elements for use in the Construction of Medical Devices	
 	

April 13, 1993
	

5,489,277*	
 	

Device having a radiopaque marker for endoscopic accessories and method of making same	
 	

February 6, 1996
	

	*
	These
patents, originally owned by ACT Medical, acquired by MedSource Technologies, Newton Inc., have been licensed to Boston Scientific Corporation ("BSC"). The technology is
used in a number of their products. MedSource Technologies, Newton Inc. receives royalties from BSC for any products not manufactured by MedSource Technologies, Newton Inc. For products
manufactured by MedSource Technologies, Newton Inc. for BSC, no royalties are due to MedSource Technologies, Newton Inc. The license agreement restricts MedSource Technologies,
Newton Inc.'s use of the patented technology for products sold to BSC's direct competitors.

	**
	This
patent, originally owned by Danforth Medical, later a division of ACT Medical, acquired by MedSource Technologies, Newton Inc., has been licensed to Tyco. The
license has some exclusivity clauses and it may not be possible to license it to others. MedSource Technologies, Newton Inc. receives royalties from Tyco for the life of the patent. 

   

Schedule 5 

MEDSOURCE TRENTON, INC.  

Patents  

i.    US Patents 

	Patent No.
 
	 	Title
	 	Issue Date

	5,888,436	 	Manufacture of Variable Stiffness Microtubing	 	March 30, 1999
	

6,045,734*	
 	

Process of Making a Catheter	
 	

April 4, 2000
	

6,314,856	
 	

Manufacture of Variable Stiffness Microtubing	
 	

November 13, 2001
	

6,323,413	
 	

Microtubing with Integral Thermocouple	
 	

November 27, 2001
	

6,616,996	
 	

Variable stiffness microtubing and method of manufacture	
 	

September 9, 2003

ii.    US Patent Applications 

	Application No.
 
	 	Title
	 	Issue Date

	08/480,411	 	Improved Variable Stiffness Microtubing and Methods of Manufacture	 	June 7, 1995
	

	*
	MedSource
Trenton, Inc. is a co-owner of this patent. MedSource Trenton, Inc. has licensed Luther Research Partners, L.L.C. to practice the patent so long as MedSource
Trenton, Inc. is the tubing supplier for the products. 

CYCAM, INC.  

Patents  

i.    US Patents 

	Patent No.
 
	 	Title
	 	Issue Date

	5,258,098*	 	Method of production of a surface adapted to promote adhesion	 	November 2, 1993
	

5,507,815*	
 	

Random surface protrusion on an implantable device	
 	

April 16, 1999
	

5,922,029*	
 	

Surface for use on an implantable device and method of production therefor	
 	

July 13, 1999
	

6,193,762*	
 	

Surface for use on an implantable device	
 	

February 27, 2001

ii.    US Patent Applications 

	Application No.
 
	 	Title
	 	Issue Date

	    	 	 	 	 
	

	*
	These
patents are jointly owned by Cycam, Inc. and Tech Met, Inc. pursuant to certain assignment agreements originating from the inventors. Cycam's rights under these
patents are restricted by a License Agreement with Tech Met dated June 13, 1991. 

  

Schedule 5 

UTI CORPORATION, a Pennsylvania corporation  

Patents  

	Title
 
	 	Jurisdiction
	 	Patent No.

(App. No.)
	 	Issue Date

(App. Date)

	Multilayer composite tubular structure and method of making	 	US	 	5,858,556	 	1/12/1999
	

Thermionic cathode with continuous bimetallic wall	
 	

US	
 	

5,729,084	
 	

3/17/1998
	

Hermetic module containing microwave component	
 	

US	
 	

5,070,314	
 	

12/03/1991
	

Thermionic cathode continuous bimetallic wall having varying wall thickness and internal blackening	
 	

US	
 	

5,422,536	
 	

06/06/1995
	

Graphical interface for robot	
 	

US	
 	

5,511,147	
 	

06/23/1996

Foreign  

	Title
 
	 	Jurisdiction
	 	Patent No.

(App. No.)
	 	Issue Date

(App. Date)

	Kinetic Energy Penetrator	 	CN	 	1224648	 	07/28/1987
	

Multilayer Composite Tubular Structure	
 	

TAIW	
 	

104017	
 	

06/21/1999
	

Multilayer Composite Tubular Structure	
 	

Argentine	
 	

AR011062B1	
 	

06/20/2003
	

Multilayer Composite Tubular Structure	
 	

Australia	
 	

733023	
 	

08/16/2001
	

Multilayer Composite Tubular Structure	
 	

Brazil	
 	

PI 9714324-3	
 	

03/19/2002
	

Multilayer Composite Tubular Structure	
 	

Canada	
 	

 	
 	

(APP DATE)

12/03/1997
	

Multilayer Composite Tubular Structure	
 	

China	
 	

 	
 	

(APP DATE)

12/03/1997
	

Multilayer Composite Tubular Structure	
 	

European PCT	
 	

 	
 	

(APP DATE)

12/03/1997
	

Multilayer Composite Tubular Structure	
 	

Hong Kong	
 	

 	
 	

(APP DATE)

08/23/2000
	

Multilayer Composite Tubular Structure	
 	

Israel	
 	

 	
 	

(APP DATE)

09/29/1999
	

Multilayer Composite Tubular Structure	
 	

Japan	
 	

 	
 	

(APP DATE)

12/03/1997

   

Schedule 5 

MEDICAL DEVICE MANUFACTURING, INC.  

Patents  

None 

AMERICAN TECHNICAL MOLDING  

Patents  

None 

NOBLE-MET, LTD.  

Patents  

	Title
 
	 	Jurisdiction
	 	Patent No.

(App. No.)
	 	Issue Date

(App. Date)

	Metal composite tube for biomedical applications	 	US	 	6,364,902	 	4/2/2002
	

Vascular filter	
 	

US	
 	

6,187,025	
 	

2/13/2001

G&D, INC. d/b/a Star Guide Corporation  

Patents  

	Title
 
	 	Jurisdiction
	 	Patent No.

(App. No.)
	 	Issue Date

(App. Date)

	Method and apparatus for centerless grinding	 	US	 	6,244,930	 	6/12/2001

Foreign  

	Title
 
	 	Jurisdiction
	 	Patent No.

(App. No.)
	 	Issue Date

(App. Date)

	Centreless grinding tool-uses image detection module to regulate grinding mechanism	 	International (WO)	 	9824590	 	6/11/1998

UTI HOLDING COMPANY  

Patents  

None

  

Schedule 5 

SPECTRUM MANUFACTURING  

Patents  

	Title
 
	 	Jurisdiction
	 	Patent No.

(App. No.)
	 	Issue Date

(App. Date)

	Process for forming endoscopic shaver blade from elongate tube	 	US	 	5,676,012	 	10/14/1997
	

Apparatus for filtering machining liquid of an electrical discharge machine	
 	

US	
 	

5,434,381	
 	

7/18/1995

MICRO-GUIDE, INC.  

Patents  

None 

VENUSA, LTD.  

Patents  

None 

VENUSA USA  

Patents  

Foreign  

	Title
 
	 	Country
	 	Patent No.

(App. No.)
	 	Issue Date

(App. Date)

	Flexible Container for Enteral Feeding Fluids	 	Australia	 	AU200071126	 	03/13/2002
	

Flexible Container for Enteral Feeding Fluids Will Not Leak When in Horizontal Position	
 	

World Patent	
 	

WO200217847 (PCT)	
 	

03/07/2002

   

Schedule 5 

Trademark Registrations and Applications owned by each Grantor  

MEDSOURCE TECHNOLOGIES, INC.  

Trademarks  

i.    US Registrations: 

	Mark
 
	 	Reg. No.
	 	Reg. Date

	DYNABITE (stylized)	 	1,806,708	 	November 23, 1993
	

MEDSOURCE TECHNOLOGIES	
 	

2,746,010	
 	

August 5, 2003
	

MEDSOURCE TECHNOLOGIES logo	
 	

2,746,011	
 	

August 5, 2003

ii.    US Applications: 

	Mark
 
	 	Appln. No.
	 	Filing Date

	DESIGN FOR PROCESS ESCELLENCE	 	76/538,838	 	August 20, 2003
	

DPEX	
 	

76/541,218	
 	

August 20, 2003
	

MEDSOURCE	
 	

76/546,091	
 	

September 22, 2003

iii    Foreign Registrations 

	Mark
 
	 	Reg. No.
	 	Reg. Date
	 	Country

	MEDSOURCE TECHNOLOGIES logo	 	30150989	 	September 24, 2002	 	Germany
	

MEDSOURCE	
 	

30149960	
 	

August 14, 2001	
 	

Germany
	

MEDSOURCE TECHNOLOGIES logo	
 	

002347458	
 	

March 27, 2003	
 	

EC
	

MEDSOURCE	
 	

002338077	
 	

June 13, 2003	
 	

EC

MEDSOURCE TECHNOLOGIES, LLC  

Trademarks  

i.    US Registrations 

	Mark
 
	 	Reg. No.
	 	Reg. Date

	INTEGRATED OUTSOURCING	 	2,523,583	 	December 25, 2001

   

Schedule 5 

BRIMFIELD PRECISION, LLC  

Trademarks  

i.    US Registrations 

	Mark
 
	 	Reg. No.
	 	Reg. Date

	BRIMFIELD	 	1,303,505	 	November 6, 1984

KELCO ACQUISITION LLC  

Trademarks  

None 

HAYDEN ACQUISITION, LLC  

Trademarks  

None 

NATIONAL WIRE & STAMPING, INC.  

Trademarks  

None 

PORTLYN, LLC  

Trademarks  

None 

TEXCEL, INC.  

Trademarks  

None 

THE MICROSPRING COMPANY, LLC  

Trademarks  

i.    US Applications 

	Mark
 
	 	Appln. No.
	 	Filing Date

	STONE CONE	 	76/277,067	 	June 27, 2001

ii    Foreign Registrations 

	Mark
 
	 	Reg. No.
	 	Reg. Date
	 	Country

	STONE CONE	 	002500379	 	June 6, 2003	 	EU

   

Schedule 5 

TENAX, LLC  

Trademarks  

i.    US Registrations  

	Mark
 
	 	Reg. No.
	 	Reg. Date

	TENAX	 	1,407,951	 	September 2, 1986

A.P.X. ACQUISITION CORP.  

Trademarks  

None 

THERMAT ACQUISITION CORP.  

Trademarks  

i.    US Registrations  

	Mark
 
	 	Reg. No.
	 	Reg. Date

	THERMAT	 	2,470,824	 	July 24, 2001

   

Schedule 5 

MEDSOURCE TECHNOLOGIES, NEWTON INC.  

Trademarks
  

None 

MEDSOURCE TRENTON, INC.  

Trademarks
  

None 

CYCAM, INC.  

Trademarks

	i.
	US
Registrations 

	Mark
 
	 	Reg. No.
	 	Reg. Date

	CHEMTEX	 	1,801,133	 	October 26, 1993

UTI CORPORATION, a Pennsylvania corporation  

Trademarks  

	Trademark
 
	 	Jurisdiction
 
	 	Reg. No (App. No.)
	 	Reg. Date (App. Date)

	TRIPLEX	 	US	 	2,843,508	 	10/3/2001
	

UTI and design	
 	

US	
 	

2,529,695	
 	

1/15/2002
	

Design only	
 	

US	
 	

2,291,546	
 	

11/9/1999
	

UNIFORM TUBES, INC.	
 	

US	
 	

1,430,544	
 	

2/24/1987
	

UTI and design	
 	

US	
 	

1,401,860	
 	

7/22/1986
	

UTITEC	
 	

US	
 	

1,319,886	
 	

2/12/1985
	

KOR-LESS	
 	

US	
 	

926,729	
 	

1/11/1972
	

Miscellaneous Design	
 	

US	
 	

2291546	
 	

 

Schedule
5 

Foreign  

	Trademark
 
	 	Country
 
	 	Reg. No.

(App. No.)
	 	Status

	TUBING EXPRESS	 	Benelux	 	494383	 	Registered
	

UTI (Stylized)	
 	

Canada	
 	

10901100	
 	

Pending
	

TRIPLEX	
 	

Canada	
 	

CA 111719800	
 	

Pending
	

UTI (& Design)	
 	

Community Trademark	
 	

1954858	
 	

Registered
	

EDIMAX TRANSOR	
 	

Germany	
 	

1145403	
 	

Registered
	

MICRO-COAX	
 	

Italy	
 	

865068	
 	

Registered
	

UTIFLEX	
 	

Italy	
 	

864573	
 	

Registered
	

UT and design	
 	

Italy	
 	

810405	
 	

Registered
	

T-CIRCUIT	
 	

Italy	
 	

507656	
 	

Registered
	

UTI MICRO COAX (& Design)	
 	

Switzerland	
 	

378829	
 	

Registered
	

Miscellaneous Design	
 	

United Kingdom	
 	

2000364	
 	

Registered
	

TUBING EXPRESS	
 	

United Kingdom	
 	

1465024	
 	

Registered
	

EDIMAX TRANSOR	
 	

United Kingdom	
 	

1362927	
 	

Registered
	

UTI (& Design)	
 	

United Kingdom	
 	

B1243106	
 	

Registered
	

TUBING EXPRESS	
 	

France	
 	

1724761	
 	

Registered

MEDICAL DEVICE MANUFACTURING, INC.  

Trademarks
  

None 

AMERICAN TECHNICAL MOLDING  

Trademarks
  

None 

NOBLE-MET, LTD.  

Trademarks
  

None 

Schedule
5 

G&D, INC.  

Trademarks

	Trademark
 
	 	Jurisdiction
 
	 	Reg. No

(App. No.)
	 	Reg. Date

(App. Date)

	STAR GUIDE and Design	 	US	 	2,218,461	 	01/19/1999

UTI HOLDING COMPANY  

Trademarks
  

None 

SPECTRUM MANUFACTURING  

Trademarks  

	Trademark
 
	 	Jurisdiction
 
	 	Reg. No

(App. No.)
	 	Reg. Date (App. Date)

	THE BOSS	 	California	 	105,982	 	2/01/2000

MICRO-GUIDE, INC.  

Trademarks
  

None 

VENUSA, LTD.  

Trademarks

	Trademark
 
	 	Jurisdiction
 
	 	Reg. No

(App. No.)
	 	Reg. Date

(App. Date)

	Design only	 	US	 	2,029,658	 	1/14/1997
	

Design only	
 	

US	
 	

2,026,474	
 	

12/31/1996
	

Design only	
 	

US	
 	

2,029,657	
 	

1/14/1997
	

STIL VEN	
 	

US	
 	

1,257,481	
 	

11/15/1983
	

V stylized letter	
 	

US	
 	

1,252,233	
 	

9/27/1983
	

FLU VEN	
 	

US	
 	

1,254,446	
 	

10/18/1983

Schedule
5 

Copyright registrations owned by each Grantor  

MEDSOURCE TECHNOLOGIES, INC.  

Copyrights
  

None 

MEDSOURCE TECHNOLOGIES, LLC  

Copyrights
  

None 

BRIMFIELD PRECISION, LLC  

Copyrights
  

None 

KELCO ACQUISITION LLC  

Copyrights
  

None 

HAYDEN ACQUISITION, LLC  

Copyrights

	Work
 
	 	Reg. No.
	 	Reg. Date

	1995 Hayden Precision	 	TXu 718-685	 	December 18, 1995
	

Hayden Precision Industries Operations Computer Program	
 	

TXu 479-773	
 	

April 19, 1991

NATIONAL WIRE & STAMPING, INC.  

Copyrights
  

None 

PORTLYN, LLC  

Copyrights
  

None 

TEXCEL, INC.  

Copyrights
  

None 

Schedule
5 

THE MICROSPRING COMPANY, LLC  

Copyrights
  

None 

TENAX, LLC  

Copyrights
  

None 

A.P.X. ACQUISITION CORP.  

Copyrights
  

None 

THERMAT ACQUISITION CORP.  

Copyrights
  

None 

MEDSOURCE TECHNOLOGIES, NEWTON INC.  

Copyrights
  

None 

MEDSOURCE TRENTON, INC.  

Copyrights
  

None 

CYCAM, INC.  

Copyrights
  

None 

UTI CORPORATION, a Pennsylvania corporation  

Copyrights

	Title
 
	 	Registration Date
	 	Registration No.

	Job catalog RPG programs SIPLIB	 	5/17/1986	 	TXu238874
	

Master Management information and control system	
 	

6/13/1984	
 	

TXu169637
	

The TR-Graphical interface	
 	

5/7/1993	
 	

TXu561981

Schedule
5 

MEDICAL DEVICE MANUFACTURING, INC.  

Copyrights
  

None 

AMERICAN TECHNICAL MOLDING  

Copyrights
  

None 

NOBLE-MET, LTD.  

Copyrights
  

None 

G&D, INC.  

Copyrights
  

None 

UTI HOLDING COMPANY  

Copyrights
  

None 

SPECTRUM MANUFACTURING  

Copyrights
  

None 

MICRO-GUIDE, INC.  

Copyrights
  

None 

VENUSA, LTD.  

Copyrights
  

None 

Schedule
5 

Patent Licenses, Trademark Licenses, Trade Secret Licenses and Copyright Licenses of each Grantor  

THERMAT  

	1.
	License
Agreement dated December 2, 1995 between Witec Cayman, Patents, Ltd. and Thermat Precision Technology, Inc.

	2.
	Agreement
dated June 1, 1992 between Thermat, Inc. and PCC Airfoils, Inc. regarding Patent No. 5,332,537.

	3.
	License
Agreement dated May 15, 2000 between Thermat Acquisition Corp. and Karl Frank Hens.

	4.
	License
Agreement dated September 28, 1999 between Thermat Precision Technology, Inc. and Zimmer, Inc.

	5.
	Non-Exclusive
License and Supply Agreement dated September 24, 1999 between Thermat Precision Technology, Inc. and Net Shape Technologies, Ltd.

	6.
	Agreement
dated June 5, 2002 between MedSource Technologies, Inc. and Karl Frank Hens. 

CYCAM  

	1.
	Agreement
and License dated June 13, 1991 by and between Cycam, Inc. and Tech Met Company.

	2.
	Patent
License Agreement dated November 1, 2000 by and between Islet Sheet Medical, LLC and Cycam, Inc. granting certain exclusive rights to Cycam under U.S. Patent
No. 5,855,613 and related patent applications.

	3.
	Manufacturing
Services and Production Agreement dated February 5, 1999 between DePuy Orthopaedics, Inc. and Cycam, Inc. 

ACT  

	1.
	Intellectual
Property Agreement effective as of June 26, 2000 between Bard Access Systems, Inc. and ACT.

	2.
	Development
Contract dated as of April 3, 2000 between Smith & Nephew Endoscopy, Inc. and ACT.

	3.
	Omnibus
OEM Manufacturing and Development Agreement effective January 1, 1996 between ACT Medical and Boston Scientific Corporation and amendments thereto. 

Schedule
5 

	4.
	License
Agreement dated November 11, 1993 between Innerdyne Medical and Danforth Medical, Inc. 

MEDSOURCE TRENTON, INC.  

	1.
	License
Agreement dated February 12, 2000 between Luther Research Partners L.L.C. and MedSource Trenton, Inc.

	2.
	Supply
Agreement dated November 15, 2001 between HV Technologies, Inc. and Boston Scientific Scimed, Inc. and Previous Agreement defined therein. 

MEDSOURCE TECHNOLOGIES, INC.  

	1.
	License
Agreement dated November 29, 2000 between Oracle and MedSource Technologies, Inc.

	2.
	Purchase
and Sale Agreement dated July 2, 2001 between Quantum Manufacturing Technologies, Inc. and MedSource Technologies, Inc. and related Sublicense Agreement
referenced therein.

	3.
	Microsoft
Business Agreement dated July 26, 2002 between MSLI, GP and MedSource Technologies, Inc.

	4.
	Microsoft
Volume License Confirmation dated September 17, 2002 between MSLI, GP and MedSource Technologies, Inc. 

MEDSOURCE TECHNOLOGIES, LLC  

	1.
	Master
License Agreement dated July 31, 2001 between Optio Software, Inc. and MedSource Technologies, LLC and Addendum.

	2.
	Development
Rights and License Agreement dated as of January 1, 2001 between Seedling Enterprises, LLC and MedSource, LLC.

	3.
	Development
Contract for Medical Instrumentation dated November 11, 2001 between Ethicon, Inc. and MedSource Technologies, LLC.

	4.
	License,
Supply and Distribution Agreement dated June 19, 2001 between Boston Scientific Corporation and MedSource Technologies, LLC and Amendment thereto. 

Schedule
5 

THE MICROSPRING COMPANY, LLC  

	1.
	Assignment
and Royalty Agreement dated January 12, 1998 between Stephen P. Dretler, MD and MicroSpring Company, Inc. 

UTI CORPORATION, a Pennsylvania corporation  

	1.
	"Consent
and Release Agreement" dated as of December 1, 2003 between UTI Corporation and Medical Device Investment Holdings Corporation.

	2.
	"Distribution
Agreement" dated as 10/2/89 between UTI Corporation and Intech Techology N.V.

	3.
	"License
and Royalty Sharing Agreement" dated as of 12/5/89 between UTI Corporation and Jon L. Turino.

	4.
	"License
and Technical Assistance Agreement" dated as of June 1, 2000 between UTI Corporation and Medical Device Investment Holdings Corporation assigned pursuant to an
"Assignment and Assumption Agreement" dated as of January 2004 between Abbott Vascular Devices Ireland Limited and Medical Device Investment Holdings Corporation. 

MEDICAL DEVICE MANUFACTURING, INC.  

None. 

AMERICAN TECHNICAL MOLDING  

None. 

NOBLE-MET, LTD.  

None. 

G&D, INC.  

None. 

UTI HOLDING COMPANY  

None. 

SPECTRUM MANUFACTURING  

None. 

MICRO-GUIDE, INC.  

None.

VENUSA, LTD.  

	1.
	"Software
License and Support Agreement" dated as of January 22, 1999 between Venusa, Ltd. and Bann USA Inc. 

Schedule
5 

	2.
	"Sourcing
Agreement" dated as of February 28, 2003 between Venusa, Ltd. and Cedic, s.r.l. an Italian company. 

Domain Names  

	Domain Name
 
	 	Owner

	spectrumedm.com	 	UTI Corporation (PA)
	

uticorporation.biz	
 	

UTI Corporation (PA)
	

wirecomponents.com	
 	

G&D, Inc. d/b/a Star Guide Corporation
	

starguide.com	
 	

G&D, Inc. d/b/a Star Guide Corporation
	

precisionwirecomponent.com	
 	

G&D, Inc. d/b/a Star Guide Corporation
	

precisionwire.com	
 	

G&D, Inc. d/b/a Star Guide Corporation
	

medicalwire.com	
 	

G&D, Inc. d/b/a Star Guide Corporation
	

micro-guide.com	
 	

Micro-Guide, Inc.
	

venusa.com	
 	

Venusa Ltd.
	

medsourcetech.com	
 	

MedSource Technologies, Inc.
	

cycaminc.com	
 	

MedSource Technologies, Inc.
	

medsourcetech.net	
 	

MedSource Technologies, Inc.
	

medsourcetechnologies.com	
 	

MedSource Technologies, Inc.
	

texcelaser.com	
 	

Texcel, Inc.

Schedule
5 

 
 

Schedule 6
  TO PLEDGE AND SECURITY AGREEMENT    
    

	Name of Grantor
 
	 	Commercial Tort Claims

	None.	 	 

Schedule
6 

 
 

ANNEX A    
    

UTI Corporation, a Maryland corporation, and its subsidiaries

Option Schedule  

       

Schedule
6 

 
 

ANNEX B    
    

MedSource Technologies, Inc. and its subsidiaries

Option Schedule  

       

Schedule
6 

 
 

Exhibit A
  TO PLEDGE AND SECURITY AGREEMENT    
    

 
 

PLEDGE SUPPLEMENT    
    

        This PLEDGE SUPPLEMENT, dated as of [mm/dd/yy], is delivered by  [name of grantor] a
[name of state of organization] [type of
organization] ("Grantor") pursuant to the Pledge and Security Agreement, dated as of June 30, 2004 (as it may
be from time to time amended, restated, amended and restated, supplemented or otherwise modified, the "Security Agreement"), between  MEDICAL DEVICE MANUFACTURING,
 INC., the other Grantors named therein, and CREDIT SUISSE FIRST BOSTON, acting through its
Cayman Islands Branch, as Collateral Agent. Capitalized terms used herein not otherwise defined herein shall have the meanings ascribed thereto in the Security Agreement. 

        Grantor
hereby confirms the grant to Collateral Agent set forth in the Security Agreement of, and does hereby grant to Collateral Agent, a security interest in all of Grantor's right,
title and interest in and to all Collateral to secure the Secured Obligations, in each case whether now or hereafter existing or in which Grantor now has or hereafter acquires an interest and wherever
the same may be located. Grantor represents and warrants that the attached Supplements to Schedules accurately and completely set forth all additional information required pursuant to the Security
Agreement and hereby agrees that such Supplements to Schedules shall constitute part of the Schedules to the Security Agreement. 

        IN WITNESS WHEREOF, Grantor has caused this Pledge Supplement to be duly executed and delivered by its duly authorized officer as of
[mm/dd/yy]. 

	 	 	[NAME OF GRANTOR]
	

 	
 	
By:	

 Name:

Title

Exhibit
A 

 
 

Supplement to Schedule 1
  TO PLEDGE AND SECURITY AGREEMENT    
    

Additional
Information: 

	(A)
	Full
Legal Name, Type of Organization, Jurisdiction of Organization, Chief Executive Office/Sole Place of Business and Organizational Identification Number of each Grantor: 

	Full Legal Name
 
	 	Type of Organization
	 	Jurisdiction of

Organization
	 	Chief Executive

Office/Sole Place

of Business
	 	Organization I.D.#

       

 

	(B)
	Other
Names (including any Trade-Name or Fictitious Business Name) under which each Grantor has conducted business for the Five Years Preceding the Closing Date: 

	Full Legal Name
 
	 	Trade Name or Fictitious Business Name

       

 

	(C)
	Changes
in Name, Jurisdiction of Organization, Chief Executive Office or Sole Place of Business and Corporate Structure within the Five Years Preceding the Closing Date: 

	Name of Grantor
 
	 	Date of Change
	 	Description of Change

       

 

	(D)
	Financing
Statements: 

	Name of Grantor
 
	 	Filing Jurisdiction(s)

Exhibit
A 

 
 

Supplement to Schedule 2
  TO PLEDGE AND SECURITY AGREEMENT    
    

Additional
Information: 

	Name of Grantor
 
	 	Location of Equipment and Inventory

Exhibit
A 

 
 

Supplement to Schedule 3
  TO PLEDGE AND SECURITY AGREEMENT    
    

        Additional
Information: 

        Pledged
Stock: 

        Pledged
Partnership Interests: 

        Pledged
Partnership Interests Elected to be Treated as Securities: 

        Pledged
LLC Interests: 

        Pledged
LLC Interests Elected to be Treated as Securities: 

        Pledged
Trust Interests: 

        Pledged
Debt: 

        Securities
Account: 

        Commodities
Accounts: 

        Deposit
Accounts: 

Exhibit
A 

 
 

Supplement to Schedule 4
  TO PLEDGE AND SECURITY AGREEMENT    
    

Additional
Information: 

	Name of Grantor
 
	 	Description of Letters of Credit

Exhibit
A 

 
 

Supplement to Schedule 5
  TO PLEDGE AND SECURITY AGREEMENT    
    

Additional
Information: 

	(A)
	Copyrights

	(B)
	Copyright
Licenses

	(C)
	Patents

	(D)
	Patent
Licenses

	(E)
	Trademarks

	(F)
	Trademark
Licenses

	(G)
	Trade
Secret Licenses

	(H)
	Intellectual
Property Exceptions 

Exhibit
A 

 
 

Supplement to Schedule 6
  TO PLEDGE AND SECURITY AGREEMENT    
    

Additional
Information: 

	Name of Grantor
 
	 	Commercial Tort Claims

Exhibit
A 

QuickLinks

Exhibit 4.6

TABLE OF CONTENTS

Schedule 1 TO PLEDGE AND SECURITY AGREEMENT

GENERAL INFORMATION

Schedule 2 TO PLEDGE AND SECURITY AGREEMENT

Schedule 3 TO PLEDGE AND SECURITY AGREEMENT

INVESTMENT RELATED PROPERTY

Schedule 4 TO PLEDGE AND SECURITY AGREEMENT

Schedule 5 TO PLEDGE AND SECURITY AGREEMENT

Schedule 6 TO PLEDGE AND SECURITY AGREEMENT

ANNEX A

ANNEX B

Exhibit A TO PLEDGE AND SECURITY AGREEMENT

PLEDGE SUPPLEMENT

Supplement to Schedule 1 TO PLEDGE AND SECURITY AGREEMENT

Supplement to Schedule 2 TO PLEDGE AND SECURITY AGREEMENT

Supplement to Schedule 3 TO PLEDGE AND SECURITY AGREEMENT

Supplement to Schedule 4 TO PLEDGE AND SECURITY AGREEMENT

Supplement to Schedule 5 TO PLEDGE AND SECURITY AGREEMENT

Supplement to Schedule 6 TO PLEDGE AND SECURITY AGREEMENTQuickLinks
 -- Click here to rapidly navigate through this document

Exhibit 4.7  

 
 

AMENDED AND RESTATED SHAREHOLDERS' AGREEMENT    
    

        THIS AMENDED AND RESTATED SHAREHOLDERS' AGREEMENT dated as of June 30, 2004 (this "Agreement") is made by and among UTI Corporation, a Maryland
corporation, as successor to MDMI Holdings, Inc., a Colorado corporation, f/k/a Medical Device Manufacturing, Inc. (the "Company"), KRG/CMS L.P. (as
successor-in-interest to KRG Capital Fund I, L.P., KRG Capital Fund I (FF), L.P., KRG Capital Fund I (PA), L.P., KRG Capital Fund I (GER), L.P., KRG Co-Investment,
L.L.C., CMS Diversified Partners, CMS Co-Investment Subpartnership and CMS PEP XIV Co-Investment Subpartnership) ("KRG"), DLJ Merchant Banking Partners III, L.P., DLJ Offshore
Partners III-1, C.V., DLJ Offshore Partners III-2, C.V., DLJ Offshore Partners III, C.V., DLJ MB Partners III GmbH & Co. KG, Millennium Partners II, L.P. and MBP III
Plan Investors, L.P. (collectively, "DLJMB" and individually, a "DLJMB Fund"), certain other shareholders of the Company listed on Schedule I to
this Agreement, and such other investors as may from time to time become a party to this Agreement. This Agreement shall amend, supersede and replace the Existing Shareholders' Agreement (as defined
below). 

WITNESSETH  

        WHEREAS, the Company, KRG, and certain other of the investors listed on Schedule I to this Agreement
entered into that certain Shareholders' Agreement dated July 6, 1999 which was later amended by those certain First Amendment to Shareholders' Agreement dated as of May 31, 2000 and
Second Amendment to Shareholders' Agreement dated as of February 24, 2003 (the "Existing Shareholders' Agreement"); 

        WHEREAS,
in connection with the investment by DLJMB in 7,568,980 shares of the Company's Class A-8 Convertible Preferred Stock and warrants to purchase additional
shares of such class of preferred stock, the parties to the Existing Shareholders' Agreement desire to (1) amend the Existing Shareholders' Agreement to admit DLJMB as a party, to reconstitute
the composition of the Company's board of directors and to make certain other modifications (collectively, the "DLJMB Amendments") and (2) to restate the Existing Shareholders' Agreement
incorporating the DLJMB Amendments and all prior amendments solely for purposes of clarity; and 

        WHEREAS,
pursuant to Section 17 of the Existing Shareholders' Agreement, a majority in interest of the Holders has consented to the DLJMB Amendments in writing (a copy of which
written consent is attached hereto). 

        NOW,
THEREFORE, in consideration of the premises and the mutual promises set forth in this Agreement, the parties agree as follows: 

AGREEMENT  

        1. Definitions. 

        (a)   Affiliate. The term "Affiliate" shall mean any natural person, corporation, trust, joint venture, association, company,
firm, partnership, limited liability company or other entity or government or governmental authority which, directly or indirectly, controls, is controlled by or is under common control with a Holder,
where "control" (including "controlling," "controlled by" and "under common control with") of a such a person or entity means the possession, direct or indirect, of the power to direct or cause the
direction of the management and policies of such person or entity, whether through the ownership of equity, by contract or otherwise. 

        (b)   Common Stock. The term "Common Stock" shall mean the common stock of the Company, $.01 par value per share. 

 

        (c)   Preferred Stock. The term "Preferred Stock" shall mean all preferred stock authorized under the Articles of Incorporation
of the Company, as it may be amended or restated from time to time. 

        (d)   Holders. The term "Holders" shall mean the persons or entities party to this Agreement who have acquired Equity
Securities and their permitted transferees pursuant to the terms of this Agreement. 

        (e)   New Securities. The term "New Securities" shall mean any capital stock of the Company (whether now authorized or not),
rights, options or warrants to purchase such capital stock and securities of any type whatsoever that are, or may become, convertible into capital stock;  provided, however, that the term "New Securities" does not include: 

        (i)    securities
issued pursuant to the acquisition of stock or assets of another entity or business segment of any such entity by the Company or its subsidiaries; provided,
that such securities are issued to the owners of such acquired stock or assets; 

        (ii)   securities
issued to employees, consultants, officers or directors of the Company pursuant to any stock option, stock purchase or stock bonus plan, agreement or
arrangement approved by the Board (as defined below); 

        (iii)  securities
issued to vendors or customers or to other persons in similar commercial situations with the Company if such issuance is approved by the Board; 

        (iv)  securities
issued in connection with obtaining debt financing from a recognized financial institution, whether issued to a lender, guarantor or other person if such
issuance is approved by the Board; provided, however, that the foregoing securities shall be deemed "New Securities" for purposes of the preemptive rights pursuant to Section 4 hereof of such
Holders (and only such Holders) that have acquired Equity Securities in connection with providing debt financing to the Company or its subsidiaries; 

        (v)   securities
issued in a firm commitment, underwritten public offering pursuant to a registration under the Securities Act of 1933, as amended (the "Securities Act"); 

        (vi)  securities
issued in connection with any stock split, stock dividend or recapitalization of the Company; 

        (vii) securities
issued upon any exercise of any convertible securities, rights, options or warrants that, when issued, were subject to or exempt from the preemptive rights
under Section 4; and 

        (viii)     any
right, option or warrant to acquire any security convertible into the securities excluded from the definition of New Securities pursuant to
subsections (i) through (vii) above. 

        (f)    Equity Securities. The term "Equity Securities" shall mean any securities, including without limitation the Common Stock,
the Preferred Stock and any securities convertible into or exercisable for any shares of the foregoing, or any option, agreement or commitment to issue any of the foregoing. 

        (g)   Qualified Public Offering. The term "Qualified Public Offering" shall mean a firm commitment underwritten initial public
offering of Equity Securities of the Company that is effected pursuant to a registration statement filed and declared effective by the Securities and Exchange Commission under the Securities Act of
1933, as amended, and the rules and regulations thereunder, resulting in gross proceeds to the Company of not less than $100,000,000. 

        (h)   DLJMBP3. "DLJMBP3" shall mean DLJ Merchant Banking Partners III, L.P. 

2

 

        (i)    Shares. The term "Shares" (1) when used with respect to a particular Holder shall mean the Equity Securities
currently owned or hereinafter acquired by such Holder, and (2) when used with respect to all Holders or with reference to aggregate amounts outstanding shall mean the aggregate Equity
Securities currently or hereinafter outstanding owned by all the Holders, in each case on an as converted or as exercised (where appropriate) basis. 

        2.     Prohibited Transfers. Each Holder shall not sell, assign, transfer, pledge, hypothecate, mortgage, encumber or otherwise
dispose of, including without limitation, transfers pursuant to the laws of testate or intestate succession, marital dissolution, legal separation or otherwise by operation of law ("Transfer") all or
any Shares except as expressly provided in this Agreement; provided, however, that (i) each
Holder may Transfer all or any of his or her Shares by way of gift to any member of his or her family or to any trust for the benefit of any such family member of the Holder (ii) each Holder
may Transfer all or any of its Shares to an Affiliate, (iii) each Holder may Transfer all or any of its Shares pursuant to Rule 144 (or any successor provision) under the Securities Act
of 1933, as amended, six months subsequent to the initial public offering of the Company, (iv) each of KRG, KRG Co-Investment, LLC, KRG Capital Fund I, L.P., KRG Capital Fund
I (PA), L.P., KRG Capital Fund I (FF), L.P, KRG Capital Fund II, L.P., KRG Capital Fund II (PA), L.P., and KRG Capital Fund II (FF), L.P. may Transfer all or any of its Shares to its limited partners
or members, as the case may be, (v) Birmingham Fire Insurance Company of Pennsylvania ("Birmingham") may transfer all or any of its Shares to any private investment fund sponsored by American
International Group, Inc. ("AIG") or managed by a direct or indirect subsidiary of AIG, as the case may be and (vi) in the case of any DLJMB Fund, (A) any other DLJMB Fund, (B),
any shareholder, member or general or limited partner of any DLJMB Fund (a "DLJMB Partner"), and any corporation, partnership, limited liability company, or other entity that is an Affiliate of any
DLJMB Partner (collectively, "DLJMB Affiliates"), or (C) any trust the beneficiaries of which, or any corporation, limited liability company or partnership the stockholders, members or general
or limited partners of which, include only such DLJMB Funds or DLJMB Affiliates; and provided, further,
that any such transferee of a Holder shall agree in writing with the parties to this Agreement, as a condition to such transfer, to be bound by all of the provisions of this Agreement (each a
"Permitted Transfer"). As used herein, the word "family" shall include any spouse, lineal ancestor or descendant, brother or sister. 

        3.     Right of First Refusal. Other than a Permitted Transfer, before any Equity Securities may be Transferred by a Holder (the
"Selling Holder") such Equity Securities (the "Selling Holder Shares") shall first be offered to the Company and then to the Holders in the following manner: 

        (a)   Notice by the Selling Holder. The Selling Holder shall deliver a notice by certified mail ("Notice") to the principal
business office of the Company and to each of the Holders stating (i) his bona fide intention to sell or Transfer the Selling Holder Shares, (ii) the number of Selling Holder Shares to
be Transferred, (iii) the price and terms, if any, for which he proposes to Transfer the Selling Holder Shares and (iv) the name and address of the proposed purchaser or transferee and
that such purchaser or transferee is committed to acquire the stated number of shares on the stated price and terms. 

        (b)   Company's Right to Purchase Selling Holder Shares. The Company shall have the right at any time within thirty
(30) days of receipt of the Notice to purchase some or all of the Selling Holder Shares at the price per share specified in the Notice. 

        (c)   Notice by the Company. If the Company (or its designee(s)) desires to purchase all or any part of the Selling Holder
Shares, the Company (or its designee(s)) shall communicate in writing of its election to purchase the Selling Holder Shares to the Selling Holder and Holders ("Company Election") which communication
shall state the number of Selling Holder Shares the Company desires to purchase and shall be given in accordance with the notice requirements of this Agreement. 

3

 

        (d)   Holders' Right to Purchase Selling Holder Shares. If the Company (or its designee(s)) does not purchase all of the
Selling Holder Shares, each Holder or a designated Affiliate shall have the right within ten (10) days of receipt of the Company Election to purchase that number of the balance of the Selling
Holder Shares as shall be equal to the number of Selling Holder Shares multiplied by a fraction, the numerator of which shall be the number of Shares then owned by such Holder and its Affiliates and
the denominator of which shall be the aggregate number of Shares then owned by all of the Holders who have delivered an election to purchase the Selling Holder Shares. The amount of Selling Holder
Shares that each Holder and its Affiliates is entitled to purchase under this Section 3(d) shall be referred to as the "Pro Rata Fraction." Each Holder desiring to purchase the Selling
Holder Shares under this Section 3 shall communicate in writing of its election to purchase the Selling Holder Shares to the Selling Holder ("Shareholder Election") which communication shall
state the number of Selling Holder Shares such Holder and its Affiliates desire to purchase and shall be given in accordance with the notice requirements of this Agreement. 

        (e)   Oversubscription. Each Holder shall have the right of oversubscription such that if a Holder fails to purchase all of his
Pro Rata Fraction, the other Holder shall have the right to purchase the balance of Selling Holder Shares not so purchased. Such right of oversubscription may be exercised by the Holder by offering to
purchase more than his Pro Rata Fraction. If, as a result thereof, such oversubscription exceeds the total number of Selling Holder Shares available in respect of such oversubscription rights, the
oversubscribing Holder shall be cut back with respect to his oversubscription on a pro rata basis in accordance with his respective Pro Rata Fraction or as the Holders may otherwise agree amongst
themselves. 

        (f)    Selling Holder's Right to Sell Selling Holders Shares. Notwithstanding any of the foregoing subsections in this
Section 3, if the Company and/or the Holders do not purchase all of the Selling Holder Shares pursuant to this Section 3, each of the Company's and the Holders' right to purchase the
Selling Holder Shares shall be forfeited and the Selling Holder may Transfer all of the Selling Holder Shares to the proposed purchaser (identified in the Notice) on terms no less favorable than as
set forth in the Notice. In the event the Selling Holder does not sell the Selling Holder Shares to the proposed purchaser within 120 days after the date of the Notice, the Selling Holder shall
not sell any Selling Holder Shares without first offering to sell the Selling Holder Shares to the Company and Holders pursuant to this Section 3. 

        (g)   Notice Constitutes an Agreement to Purchase. If the Company (or its designee(s)) or the Holders elect to purchase all or
any portion of the Selling Holder Shares, the Company Notice or a Shareholder Notice delivered by the Company or any of the Holders shall be deemed to constitute a valid, legally binding and
enforceable agreement for the sale and purchase of the Selling Holder Shares. Sales of Selling Holder Shares to be sold to the Company (or its designee(s)) or to the Holders pursuant to this
Section 3 shall be made at the offices of the Company on the 45th day following the date of the Notice (or if such 45th day is not a business day, then on the next succeeding business day).
Such sales shall be effected by the delivery to the Company of a certificate or certificates evidencing the Selling Holder Shares to be purchased by the Company (or its designee(s)) or the Holders,
duly endorsed for transfer to such party, in exchange for cash payment to the Selling Holder in the amount of the purchase price therefor by the party purchasing such Selling Holder Shares. 

        4.     Preemptive Right. 

        (a)   General. If the Company issues any New Securities, it shall offer to sell to each Holder, a Ratable Portion (defined
below) of such New Securities on the same terms and conditions and at the lowest price as such New Securities are issued to any person. "Ratable Portion" shall mean that portion of such New Securities
that bear the same ratio (including for this purpose all New 

4

 

Securities
which may be purchased by the Holders pursuant to this Section 4) as the number of Shares held by such Holder bears to all Shares then outstanding. 

        (b)   Procedure. In the event that the Company proposes to undertake an issuance of New Securities, it shall give to each
Holder written notice of its intention to issue New Securities (also referred to as the "Notice"), describing the type of New Securities and the price and the general terms upon which the Company
proposes to issue such New Securities. Each Holder shall have ten (10) days from the date of receipt of any such Notice to agree in writing to purchase or allow an Affiliate to purchase his
Ratable Portion of such New Securities for the price and upon the general terms specified in the Notice by giving written notice to the Company and stating therein the quantity of New Securities to be
purchased (not to exceed his Ratable Portion). If a Holder fails to agree in writing within such ten day period to purchase or allow an Affiliate to purchase his full Ratable Portion of an offering of
New Securities (a "Nonpurchasing Holder"), then such Nonpurchasing Holder shall forfeit the right hereunder to purchase that part of his Ratable Portion of such New Securities that he did not so agree
to purchase and the Company shall promptly give the remaining Holders who timely agreed to purchase their full Ratable Portion of such offering of New Securities (a "Purchasing Holder") written notice
of the failure of the Nonpurchasing Holder to purchase his full Ratable Portion of New Securities (the "Overallotment Notice"). A Purchasing Holder shall have a right of overallotment such that the
Purchasing Holder may agree to purchase or allow an Affiliate to purchase the Nonpurchasing Holders' unpurchased Ratable Portion at any time within five (5) days after receiving the
Overallotment Notice. If more than one Purchasing Holder wishes to purchase the Nonpurchasing Holders' unpurchased Ratable Portion, the overallotment shall be divided among the Purchasing Holders
based on each such Purchasing Holder's Ratable Portion. 

        (c)   Failure to Exercise. In the event that a Holder fails to exercise the rights granted to him in
Sections 4(a) and (b) above (the "Preemptive Right") within such ten (10) plus five (5) day period, then the Company shall have 120 days thereafter to sell
the New Securities with respect to which the Holder's Preemptive Rights were not exercised, at a price and upon general terms not materially more favorable to the purchasers thereof than specified in
the Company's Notice to the Holders. In the event that the Company has not issued and sold the New Securities within such 120 day period, then the Company shall not thereafter issue or sell any
New Securities without again first offering such New Securities to the Holders pursuant to this Section 4. 

        5.     Tag-Along Rights. Subject to the provisions of Section 3 hereof and except for a Permitted Transfer
under Section 2, in the event a Holder (an "Offering Holder") intends to Transfer Shares (also referred to as "Offered Shares"), such Offering Holder shall notify each other Holder, in writing,
of such Transfer and its terms and conditions, including, without limitation, (i) his bona fide intention to sell or Transfer the Offered Shares, (ii) the number of Offered Shares to be
Transferred, (iii) the price and terms, if any, for which he proposes to Transfer the Offered Shares and (iv) the name and address of the proposed purchaser or transferee and that such
purchaser or transferee is committed to acquire the stated number of shares on the stated price and terms ("Offering Holder Notice"). Within 20 days of the date of such notice, each Holder
(other than the Offering Holder) shall notify the Offering Holder in writing (the "Co-Sale Notice") if it or he elects to participate in such Transfer. Each Holder that so notifies the
Offering Holder shall have the right to sell, at the same price and on the same terms as the Offering Holder, an amount of shares equal to the Shares the third party proposes to purchase multiplied by
a fraction, the numerator of which shall be the number of Shares issued and owned by such Holder and the denominator of which shall be the aggregate number of Shares issued and owned by the Offering
Holder and each Holder exercising its rights under this Section 5. Nothing contained in this Section 5 shall in any way limit or restrict the Offering Holder's ability to amend, modify
or terminate any agreement with a third party with respect to any Transfer of its Shares pursuant to this Section 5, and the Offering Holder shall have no liability to any Holder with respect
to 

5

 

such
amendment, modification or termination unless any of the foregoing breaches this Agreement. If no Co-Sale Notice is received during the 20-day period referred to above (or
if the Co-Sale Notice does not cover all of the Shares proposed to be Transferred), the Offering Holder shall have the right, for a 60-day period after the expiration of the
20-day period referred to above, to Transfer the Shares specified in the Offering Holder Notice (or the remaining Shares) on terms and conditions no more favorable than those stated in the
Offering Holder Notice, so long as the proposed purchaser agrees to enter into a joinder of this Agreement whereby such person shall become subject to the terms and conditions hereof. 

        6.     Drag-Along Rights. 

        (a)   General. Subject to the provisions of Section 3 and the prior approval of a majority of the directors of the
Board, in the event a Holder or Holders owning more than 75% of the issued and outstanding Shares (the "Selling Group") wish to Transfer in a bona fide arms' length sale all of the Shares then
owned by them to any person who is not an affiliate of such Selling Group (the "Proposed Transferee"), the Selling Group shall have the right (the "Drag-Along Right") upon the approval of
a majority of the directors of the Board to require all of the Holders to sell to the Proposed Transferee all of the Shares then owned by such Holders for the same per share consideration and
otherwise on the same terms received by the Selling Group. Each Holder agrees to take all steps necessary to enable it or him to comply with the provisions of this Section 6, including the
delivery of certificates for all such Shares duly endorsed or accompanied by appropriate instruments of transfer and free and clear of any liens or other encumbrances; provided, however, that in
connection with any such transaction (x) each Holder shall not be required to make any representations or warranties except those relating to (i) its own due organization and execution
and delivery of the relevant agreement, (ii) the enforceability of the relevant agreement against it and absence of conflicts with agreements and laws applicable to it and (iii) its
ownership of securities being sold by it, (y) the Holders shall not be required to provide any post-closing indemnities except as provided in clause (z) below and
(z) in the event that a portion of the purchase price is placed in escrow to support purchase price adjustment obligations post-closing (including indemnification for breaches of
representations or warranties relating to the Company and its subsidiaries), the Holders will have a pro rata portion of their purchase price placed in such escrow to be utilized to pay any such
indemnification obligations. 

        (b)   Procedure. To exercise a Drag-Along Right, the Selling Group shall, after receiving Board approval in
accordance with Section 6(a), give each Holder a written notice (the "Drag-Along Notice") containing (i) the name and address of the Proposed Transferee, and (ii) the
proposed purchase price, terms of payment and other material terms and conditions of the Proposed Transferee's offer. Each Holder shall thereafter be obligated to sell its Shares subject to such
Drag-Along Notice, provided that the sale to the Proposed Transferee is consummated within sixty (60) days of delivery of the Drag-Along Notice. If the sale is not
consummated within such 60-day period, then each Holder shall no longer be obligated to sell such Holder's shares pursuant to that specific Drag-Along Right, but each Holder's
shares shall remain subject to the provisions of this Section 6. 

        7.     Legend. Each existing or replacement certificate for Shares now owned by the Holders shall bear the following legend upon
its face: 

        "THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THE TRANSFER, ENCUMBRANCE, PLEDGE, ASSIGNMENT OR OTHER DISPOSITION
OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE CONDITIONS AND RESTRICTIONS SPECIFIED IN (1) A SUBSCRIPTION AGREEMENT, DATED AS
OF                        , BY AND BETWEEN THE
COMPANY AND A CERTAIN INVESTOR AND 

6

 

(2) AN
AMENDED AND RESTATED SHAREHOLDERS' AGREEMENT, DATED AS OF                  , 2004, BY AND AMONG THE COMPANY AND CERTAIN SHAREHOLDERS, AS THE SAME IS AMENDED AS
OF THE DATE HEREOF, AND THE
cOMPANY RESERVES THE RIGHT TO REFUSE THE TRANSFER OF SUCH SECURITIES UNTIL SUCH CONDITIONS AND RESTRICTIONS HAVE BEEN FULFILLED OR LIFTED WITH RESPECT TO SUCH TRANSFER. A COPY OF THE CONDITIONS OR
AGREEMENTS REFERENCED ABOVE MAY BE OBTAINED BY THE HOLDER HEREOF UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY." 

        Each
of the undersigned parties agrees that the Company may instruct its transfer agent to impose transfer restrictions on the shares represented by certificates bearing the legend
referred to in this Section 7 to enforce the provisions of this Agreement and the Company agrees to promptly do so. The legend shall be removed or modified upon termination of the conditions or
restrictions set forth therein. 

        8.     Voting Agreements. 

        (a)   Certificate Incorporation of the Company. The Holders acknowledge that the Certificate of Incorporation attached as  Exhibit A will be in effect as the Articles of
Incorporation, of the Company as of the date hereof. The provisions of  Exhibits A are hereby approved by, and made a part of the agreement among, the parties hereto. 

        (b)   By-Laws of the Company. The Holders acknowledge that the By-Laws attached as  Exhibit B will be in effect as the By-Laws of the Company as of the date hereof. The
provisions of  Exhibit B are hereby made a part of the agreement among the parties hereto. 

        (c)   Board of Directors. 

        (i)    The
Board of Directors of the Company (the "Board") shall initially be comprised of eleven directors (each a "Director"), subject to increase or decrease only by the
mutual written consent of
DLJMB and KRG. During the term of this Agreement and at any special or annual meeting of the Holders at which directors are to be elected to the Board, (A) DLJMB shall be entitled to designate
four directors to sit on the Board (the "DLJMB Directors"); (B) KRG shall be entitled to designate six directors to sit on the Board (the "KRG Directors"); and (C) the Chief Executive
Officer of the Company shall be designated as a director to sit on the Board, who initially shall be Ron Sparks. At any time, KRG shall have the right to reduce the number of KRG Directors to five
and, at such time, if the total number of Directors is reduced from eleven to nine then the number of DLJMB Directors shall automatically be reduced to three. At such time, DLJMB agrees to take such
actions as may be necessary to reduce the number of DLJMB Directors in accordance with the foregoing. The rights granted with respect to the Holders pursuant to subclauses (A) and (B) of
this Section 8(c)(i) shall continue with respect to such Holders until such time as the applicable Holders own less than 5% of the Company's outstanding Common Stock on a fully diluted
and fully converted basis (excluding unvested options). 

        (ii)   Any
Holder that (x) does not have the power to designate one or more directors to sit on the Board in accordance with clause (i) of this
Section 8.1(c)(i) and (y) owns at least 5% of the Company's outstanding Common Stock on a fully diluted and fully converted basis (excluding unvested options) shall have the right
to (1) appoint an observer to the Board who shall be entitled to all notices and documentary information distributed to, and to attend all meetings of, the Board generally but shall have no
voting or similar rights with respect thereto, (2) meet with, upon reasonable prior notice and request, and discuss during normal business hours the business and operations of the
Company with the Company's senior officers and representatives of KRG, in each case at locations convenient to the parties 

7

 

thereto
and (3) receive such other information relating to the Company (including industry analysis and other strategic information in the possession of the Company) as it may reasonably
request, providing that such information shall be subject in each case to confidentiality requirements as the Company deems reasonably necessary. Any observer rights exercised hereunder shall be at
the cost and expense of the Holder exercising such rights other than with respect to the provision of notices and informational materials, and no observer shall be entitled to any form of compensation
or per diem. 

        (iii)  All
Holders shall be entitled to receive those quarterly and annual financial reports of the Company provided to the Company's senior lender within 15 days of
the distribution of any such report to such senior lender. Additionally, any Holder that owns at least 2.5% of the Company's outstanding Common Stock on a fully diluted and fully converted basis
(excluding unvested options) shall have the right to receive upon request all documentary information provided to members of the Board generally. 

        (iv)  The
Board shall not reconstitute the Executive Committee without the consent of the DLJMB Directors. 

        (d)   Replacement and Removal of Directors. In the event of resignation, death, removal or disqualification of a director
selected in accordance with Section 8(c), the shareholders entitled to designate such
director shall promptly designate a replacement director (or in the case of Section 8(c)(i)(C), the new Chief Executive Officer) and in all other cases the directors by a majority vote shall
promptly designate a replacement director. The shareholders entitled to designate a director in accordance with Section 8(c) may remove their designated director(s) at any time and from time to
time, with or without cause (subject to the By-Laws of the Company as in effect from time to time and any requirements of law), in their sole discretion, and after written notice to each
of the Holders hereto of the new person to replace such director. 

        (e)   Agreement to Cooperate. In order to effectuate the provisions of this Section 8, when any action or vote is
required to be taken by any Holder pursuant to this Section 8 each Holder shall (i) use such Holder's best efforts and take all actions necessary to call, or cause the Company and the
appropriate officers and directors of the Company to call, a special or annual meeting of shareholders of the Company, or execute or cause to be executed a consent in writing in lieu of any such
meeting pursuant to the Maryland General Corporation Law or any other governing law, to effectuate such shareholder action; and (ii) vote such Holder's Shares (either in person, by proxy or by
written consent and whether owned or held of record) to take whatever action is consistent with the terms and intent of this Section 8 and is required to be taken pursuant to this Agreement. 

        (f)    Conflicting Charter or By-Law Provisions. Each Holder shall vote his, her or its Shares, and shall take all
actions necessary, to ensure that the Company's Articles of Incorporation and By-Laws do not, from time to time, conflict with the provisions of this Agreement. No Holder shall grant any
proxy or enter into or agree to be bound by any voting trust with respect to his, her or its Shares, nor shall any Holder enter into any shareholders agreement or arrangement of any kind with any
person with respect to his, her or its Shares, inconsistent with the provisions of this Agreement (whether or not such trust, agreement or arrangement is with other shareholders of Shares that are not
parties to this Agreement). 

        (g)   Subsidiary Boards. DLJMB shall be entitled to proportionate representation on all Board committees, the board of
directors of Medical Device Manufacturing, Inc. and any other subsidiaries with a board of directors substantially similar to the Board of the Company, and shall have the right to appoint one
director on the boards of directors of any subsidiary of the Company in which KRG or any of its Affiliates have at least one board representative. 

8

 

        9.     Issuance of Options. Notwithstanding anything in this Agreement to the contrary, the Company may not issue options under
its stock option plans to officers, directors and employees that exceed, in the aggregate, 10% of the then outstanding shares of Common Stock on a fully diluted and converted basis without the prior
approval of a majority in interest of the Holders. 

        10.   Notices. All notices, demands or other communications to be given or delivered under or by reason of the provisions of
this Agreement shall be in writing and shall be deemed to have been given when delivered personally to the recipient, sent to the recipient by reputable overnight courier service (charges prepaid),
mailed to the recipient by certified or registered mail, return receipt requested and postage prepaid, or transmitted by facsimile or electronic mail (with request for immediate confirmation of
receipt in a manner customary for communications of such type and with physical delivery of the communication being made by one of the other means specified in this Section 9 as promptly as
practicable thereafter). Such notices, demands and other communications shall be addressed (i) in the case of a Holder, to his address as is designated in writing from time to time by such
Holder, (ii) in the case of the Company, to its principal office, and (iii) in the case of any transferee of a party to this Agreement or its transferee, to such transferee at its
address as designated in writing by such transferee to the Company from time to time. 

        11.   Assignment of Rights. This Agreement and the rights and obligations of the parties hereunder shall inure to the benefit
of, and be binding upon, the parties' respective successors, permitted assigns and legal representatives. 

        12.   Term. This Agreement shall terminate upon the earlier of (i) immediately before (and conditioned upon) the closing
of a Qualified Public Offering or (ii) immediately before (and conditioned upon) the closing of the merger of the Company with and into a company that is publicly traded on a nationally
recognized stock exchange or over-the-counter market and the Company is not the surviving entity. 

        13.   Entire Agreement; Governing Law. This instrument contains the entire understanding of the parties with respect to the
subject matter hereof, supersedes all other agreements between or among any of the parties with respect to the subject matter hereof and cannot be altered or otherwise amended except pursuant the
terms of Section 17 below. This Agreement shall be interpreted under the laws of the State of Colorado without reference to its principles of conflicts of laws. 

        14.   Attorneys' Fees. If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the
prevailing party shall be entitled to reasonable attorneys' fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 

        15.   Spousal Consent. The spouses of the individual Holders are fully aware of, understand and fully consent and agree to the
provisions of this Agreement and its binding effect upon any community property interests or similar marital property interests in Equity Securities they may now or hereafter own, and agree that the
termination of their marital relationship with any Holder for any reason shall not have the effect of removing any Equity Securities otherwise subject to this Agreement from the coverage of this
Agreement and that their awareness, understanding, consent and agreement are evidenced by their signing this Agreement. Furthermore, each individual Holder agrees to cause his or her spouse (and any
subsequent spouse) to execute and deliver, upon the request of the company, a counterpart of this Agreement, or an Adoption Agreement in a form satisfactory to the Company. 

        16.   Remedy. Any Transfer or attempted Transfer in breach of this Agreement shall be void and of no effect; provided, that the
Company may determine to treat any attempted Transfer in breach of this Agreement, as an offer pursuant to Section 3. Additionally, the time periods set forth in Section 3 shall begin to
run as of the date the Company receives evidence satisfactory to it of such attempted Transfer. In connection with any attempted Transfer in breach of this Agreement, the Company may hold and refuse
to transfer any Equity Securities or any certificate therefor tendered to it for transfer, in 

9

 

addition
to and without prejudice to any and all other rights or remedies which may be available to it or the Holders. Each party to this Agreement acknowledges that a remedy at law for any breach or
attempted breach of this Agreement will be inadequate, agrees that each other party to that Section 3 shall be entitled to specific performance and injunctive and other equitable relief in case
of any such breach or attempted breach and further agrees to waive (to the extent legally permissible) any legal conditions required to be met for the obtaining of any such injunctive or other
equitable relief. 

        17.   Stockholders Representative. For purposes of this Agreement, each DLJMB Fund hereby consents to the appointment of
DLJMBP3, as representative (the "Stockholders Representative") of DLJMB, and as attorney-in-fact for and on behalf of DLJMB, and, subject to the express limitations set forth
below, the taking by the Stockholders Representative of any and all actions and the making of any decisions required or permitted to be taken by DLJMB under this Agreement. The Stockholders
Representative will have unlimited authority and power to act on behalf of DLJMB with respect to this Agreement (including the right to appoint the DLJMB Directors hereunder) and the disposition,
settlement or other handling of all claims, rights or obligations arising under this Agreement so long as all DLJMB Funds are treated in the same manner. DLJMB will be bound by all actions taken by
the Stockholders Representative in connection with this Agreement. In performing its functions hereunder, the Stockholders Representative will not be liable to DLJMB in the absence of gross negligence
or willful misconduct. 

        18.   Further Instruments and Actions. The parties agree to execute such further instruments and to take such further action as
may reasonably be necessary to carry out the intent of this Agreement. The parties further agree to cooperate affirmatively with the Company, to the extent reasonably requested by the Company to
enforce rights and obligations to this Agreement. 

        19.   Amendments and Waivers. Any term of this Agreement may be amended and the observance thereof may be waived (either
generally or in a particular instance and either retroactively or prospectively), only with the written consent of a majority in interest of the Holders; provided, however, that any amendment of this
Agreement that shall adversely impact any Holders of a series of Equity Securities in a manner different from other Holders shall require the written consent of 662/3% in interest of
the Holders of the series of Equity Securities so adversely affected. Notwithstanding the foregoing, no amendment to or waiver of any provision of Section 8(c)(i) of this Agreement shall
be effective without the mutual written consent of KRG and DLJMB. Any amendment or waiver effected in accordance with this Section 19 shall be binding upon the Company and the Holders. 

        20.   Rights; Severability. Unless otherwise expressly provided herein, a Holder's rights hereunder are several rights, not
rights jointly held with any other Holder. In case any provision of this Agreement shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions
shall not in any way be affected or impaired thereby. 

        21.   Specific Enforcement; Cumulative Remedies. The parties hereto acknowledge that money damages may not be an adequate
remedy for violations of this Agreement and that any party, in addition to any other rights and remedies which the parties may have hereunder or at law or in equity, may, in his or its sole
discretion, apply to a court of competent jurisdiction for specific performance or injunction or such other relief as such court may deem just and proper in order to enforce this Agreement or prevent
any violation hereof and, to the extent permitted by applicable law, each party waives any objection to the imposition of such relief. All rights, powers and remedies provided under this Agreement or
otherwise available in respect hereof at law or in equity shall be cumulative and not alternative, and the exercise or beginning of the exercise of any thereof by any party shall not preclude the
simultaneous or later exercise of any other such rights, powers or remedies by such party. 

        22.   Counterparts; Facsimile Signatures. This Agreement may be executed in counterparts, both of which need not contain the
signatures of more than one party, but both such counterparts taken 

10

 

together
will constitute one and the same Agreement. This Agreement may be executed and delivered by facsimile transmission. 

*
* * * * 

        This
amendment and restatment of the Existing Shareholders' Agreement has been effected by the written consent of a majority of the Holders pursuant to Section 17 thereof. A copy
of such written consent is attached hereto. 

11

QuickLinks

AMENDED AND RESTATED SHAREHOLDERS' AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00071-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00071-of-00352.parquet"}]]